


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:05:35Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405236" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405236</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>discon</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Discov Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Discov Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">4139</journal-id><journal-id journal-id-type="pmc-domain">discon</journal-id><journal-title-group><journal-title>Discover Oncology</journal-title></journal-title-group><issn pub-type="epub">2730-6011</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405236</article-id><article-id pub-id-type="pmcid-ver">PMC12405236.1</article-id><article-id pub-id-type="pmcaid">12405236</article-id><article-id pub-id-type="pmcaiid">12405236</article-id><article-id pub-id-type="pmid">40897950</article-id><article-id pub-id-type="doi">10.1007/s12672-025-03520-0</article-id><article-id pub-id-type="publisher-id">3520</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Mechanisms of cancer-induced neurophysiological dysfunction and therapeutic strategies</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Mujinya</surname><given-names initials="R">Regan</given-names></name><address><email>reaganmujinya1990@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Owembabazi</surname><given-names initials="E">Elna</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Usman</surname><given-names initials="IM">Ibe Michael</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Archibong</surname><given-names initials="VB">Victor Bassey</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Aja</surname><given-names initials="PM">Patrick Maduabuchi</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mwandah</surname><given-names initials="DC">Daniel Chans</given-names></name><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Terkimbi</surname><given-names initials="SD">Swase Dominic</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05701wm02</institution-id><institution>Department of Physiology, </institution><institution>Equator University of Science and Technology, </institution></institution-wrap>Masaka, Uganda </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/017g82c94</institution-id><institution-id institution-id-type="GRID">grid.440478.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0648 1247</institution-id><institution>Department of Anatomy, </institution><institution>Kampala International University, </institution></institution-wrap>Ishaka, Uganda </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/017g82c94</institution-id><institution-id institution-id-type="GRID">grid.440478.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0648 1247</institution-id><institution>Department of Biochemistry, </institution><institution>Kampala International University, </institution></institution-wrap>Ishaka, Uganda </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/017g82c94</institution-id><institution-id institution-id-type="GRID">grid.440478.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0648 1247</institution-id><institution>Department of Physiology, </institution><institution>Kampala International University, </institution></institution-wrap>Ishaka, Uganda </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00286hs46</institution-id><institution-id institution-id-type="GRID">grid.10818.30</institution-id><institution-id institution-id-type="ISNI">0000 0004 0620 2260</institution-id><institution>Department of Human Anatomy, </institution><institution>University of Rwanda, </institution></institution-wrap>Kigali, Rwanda </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/017g82c94</institution-id><institution-id institution-id-type="GRID">grid.440478.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0648 1247</institution-id><institution>Department of Pharmacology, </institution><institution>Kampala International University-Western Campus, </institution></institution-wrap>Ishaka, Uganda </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01bkn5154</institution-id><institution-id institution-id-type="GRID">grid.33440.30</institution-id><institution-id institution-id-type="ISNI">0000 0001 0232 6272</institution-id><institution>Pharmacology and Therapeutics, </institution><institution>Mbarara University of Science and Technology, </institution></institution-wrap>Mbarara, Uganda </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">478248</issue-id><elocation-id>1678</elocation-id><history><date date-type="received"><day>5</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>27</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="12672_2025_Article_3520.pdf"/><abstract id="Abs1"><sec><title>Abstract</title><p id="Par1">Neurophysiological alterations represent a growing concern in oncology, affecting both the central and peripheral nervous systems through diverse mechanisms. These include direct tumor infiltration, paraneoplastic immune responses, systemic inflammation, metabolic dysregulation, and treatment-induced neurotoxicity. Neurological complications range from cognitive impairment and peripheral neuropathy to motor deficits and autonomic dysfunction. Paraneoplastic syndromes mediated by immune cross-reactivity and inflammatory cytokines such as IL-6 and TNF-&#945; contribute to neural disruption. Cancer therapies, particularly chemotherapy, radiotherapy, and immunotherapy, increase these alterations, resulting in persistent or progressive neurological deficits. Diagnostic tools such as functional MRI, electroencephalography (EEG), cerebrospinal fluid biomarkers, and circulating tumor DNA (ctDNA) are used for earlier detection and reduced stratification risk. Management strategies incorporate neuroprotective agents (e.g., amifostine), cognitive rehabilitation, and non-invasive neuromodulation techniques. These techniques include transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). Personalized neuro-oncological care is guided by biomarker-driven profiling and digital health monitoring. Pediatric patients and long-term survivors require special attention due to vulnerability to neurodevelopmental disruption. A multidisciplinary and anticipatory approach is essential for preserving neurological function and enhancing quality of life across the cancer continuum. Advances in diagnostics and therapeutics are reshaping the integration of neurophysiology within comprehensive cancer care.</p></sec><sec><title>Graphical abstract</title><p id="Par2">
<graphic position="anchor" id="MO10" orientation="portrait" xlink:href="12672_2025_3520_Figa_HTML.jpg"/>
</p></sec></abstract><abstract id="Abs2" abstract-type="Highlights"><title>Article highlights</title><p id="Par3">
<list list-type="bullet"><list-item><p id="Par4">Cancer induces both central and peripheral neurophysiological dysfunction through direct tumor effects, paraneoplastic syndromes, systemic inflammation, and treatment-relatedtoxicity.</p></list-item><list-item><p id="Par5">Cognitive impairment (&#8220;chemo brain&#8221;) and peripheral neuropathies are among the most common neurological complications affecting quality of life and treatment adherence.</p></list-item><list-item><p id="Par6">Paraneoplastic neurological syndromes (PNS) result from immune cross-reactivity and can cause severe, rapidly progressing neurological deficits.</p></list-item><list-item><p id="Par7">Systemic inflammation and metabolic disturbances increase neural injury by disrupting blood-brain barrier integrity and promoting neuroinflammation.</p></list-item><list-item><p id="Par8">Cancer therapies, especially chemotherapy, radiotherapy, and immunotherapy, are major contributors to neurotoxicity and long-term neurological sequelae.</p></list-item><list-item><p id="Par9">Emerging diagnostic tools, including functional MRI, EEG, evoked potentials, and CSF biomarkers, offer improved detection and monitoring of neurological damage.</p></list-item></list>
</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Neuro-oncology</kwd><kwd>Cancer-related neurotoxicity</kwd><kwd>Paraneoplastic syndromes</kwd><kwd>Cognitive dysfunction</kwd><kwd>Peripheral neuropathy</kwd><kwd>Biomarkers</kwd><kwd>Neuroimaging</kwd><kwd>Rehabilitation</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec2"><title>Introduction</title><p id="Par28">Cancer is a multifaceted disease that affects the primary organ and induces widespread systemic effects, particularly the nervous system. Neurophysiological alterations in cancer patients have emerged as an important area of concern due to the impact on cognition, sensory and motor functions, and autonomic regulation. These alterations can arise from various mechanisms, including direct tumor invasion of neural tissues, paraneoplastic immune responses, metabolic dysregulation, and systemic inflammation [<xref ref-type="bibr" rid="CR45">45</xref>]. Other causes can arise as a result of the adverse effects of cancer therapies such as chemotherapy, radiotherapy, and immunotherapy. Recent advancement in early detection offers improved therapeutic innovations, with global cancer survivorship increasing with over 43&#160;million individuals [<xref ref-type="bibr" rid="CR50">50</xref>]. However, this positive trajectory is accompanied by a growing incidence of treatment-associated neurotoxic effects. Notably, cognitive impairment, often referred to as &#8220;chemo brain,&#8221; affects up to 75% of patients during or following chemotherapy, while an estimated 30&#8211;40% develop persistent or late-onset neurological dysfunctions [<xref ref-type="bibr" rid="CR4">4</xref>]. These complications include cognitive dysfunction, chemotherapy-induced peripheral neuropathy (CIPN), encephalopathy, seizures, and chronic neuropathic pain. Such deficits compromise functional independence and can lead to reduced adherence to treatment protocols, early discontinuation of potentially curative therapies, increased healthcare costs, and a significant psychosocial burden. These trends require an urgent need for integrated neuro-oncological care into standard cancer management frameworks [<xref ref-type="bibr" rid="CR62">62</xref>]. Neurophysiological changes in cancer can affect nerve conduction velocity or EEG patterns, and may also present as more severe conditions such as focal deficits or global encephalopathy [<xref ref-type="bibr" rid="CR29">29</xref>]. The interaction between tumors and the nervous system is bidirectional and complex. Tumors can alter neuronal function through mechanical compression, infiltration, or by releasing neuroactive substances and inflammatory mediators [<xref ref-type="bibr" rid="CR44">44</xref>]. Concurrently, the nervous system may influence tumor growth through neural signaling pathways, immune modulation, and hormonal responses. This further emphasised the deeper role of the neuroimmune and neuroendocrine interface in cancer biology [<xref ref-type="bibr" rid="CR30">30</xref>]. Despite a growing body of evidence highlighting the impact of cancer and its treatment on the nervous system, neurological assessment remains insufficiently integrated into routine oncology practice. The research landscape is similarly fragmented, with persistent gaps in understanding of the underlying mechanisms. The development of robust diagnostic tools and the validation of effective neuroprotective and rehabilitative interventions. Therefore, this review aims to synthesize the current understanding of cancer-related neurophysiological alterations, highlight emerging diagnostic and therapeutic strategies, and identify critical knowledge gaps to guide future clinical and translational research.</p></sec><sec id="Sec3"><title>Mechanisms of tumor-induced neurological dysfunction</title><p id="Par29">Neurological dysfunction in cancer results from complex and dynamic interactions between tumor growth, immune system activation, systemic metabolic disturbances, and neurotoxic effects of treatments. Systemic inflammation can amplify chemotherapy-related neurotoxicity, while metabolic changes may increase vulnerability to radiation-induced neural damage [<xref ref-type="bibr" rid="CR71">71</xref>]. The nature and extent of neural injury, both structural and functional, vary depending on tumor type, disease stage, treatment modality, and individual patient factors. The following subsections explore the specific molecular and cellular mechanisms driving tumor-associated neurological dysfunction.</p><sec id="Sec4"><title>Direct tumor invasion and mechanical compression</title><p id="Par30">Neurological dysfunction can arise through two major and severe pathological mechanisms, including direct infiltration of neural tissue by the tumor and mechanical compression of surrounding nervous structures. Tumors involving the central or peripheral nervous system can physically infiltrate or compress surrounding neural structures, disrupting local tissue structure and impairing neurological functions. This disruption can compromise neuronal signaling, blood flow, and cerebrospinal fluid dynamics, leading to a wide range of clinical manifestations as depicted by Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>. The nature and severity of symptoms depend largely on the anatomical location, size, and growth rate of the tumor. For example, the glioblastoma located in the frontal lobe commonly presents with personality changes, impaired executive function, apathy, or disinhibition due to its impact on the prefrontal cortex [<xref ref-type="bibr" rid="CR28">28</xref>]. Temporal lobe lesions can result in memory impairment, language difficulties, or complex partial seizures, while tumors in the parietal lobe can cause sensory deficits, spatial disorientation, or apraxia. Similarly, cerebellar tumors may manifest as ataxia, dysmetria, or nystagmus due to involvement of motor coordination pathways [<xref ref-type="bibr" rid="CR59">59</xref>]. In the spinal cord, metastatic lesions from cancers such as breast, lung, or prostate can compress neural elements. These complication results in back pain, radiculopathy, motor weakness, sensory disturbances, and autonomic dysfunction such as bladder or bowel incontinence. The level of spinal involvement dictates the pattern of deficits. For example, cervical cord compression can cause quadriparesis while thoracic involvement typically results in paraparesis [<xref ref-type="bibr" rid="CR23">23</xref>]. The clinical presentations of direct tumor invasion and mechanical compression are predictable, directly correlating with the specific neural structures that are compromised. This spatial relationship suggests why precise neuro-anatomical localization is important for both diagnosis and effective therapeutic intervention.</p><p id="Par31">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Mechanisms of tumor-induced neurological dysfunction. This figure depicts the local and systemic mechanisms by which tumors induce neurological dysfunction. Locally, tumors exert mass effect, cause midline shift, and infiltrate brain parenchyma, leading to structural and functional disruption. Systemically, elevated cytokines (IL-6, TNF-&#945;) and VEGF increase blood-brain barrier permeability and promote neuroinflammation. Ionic imbalance (Ca&#178;&#8314;, Na&#8314;) and microglial activation further contribute to neuronal injury. Cancer therapies such as chemotherapy, immunotherapy, and radiation aim to counteract these effects and restore neurological integrity</p></caption><graphic id="d33e439" position="float" orientation="portrait" xlink:href="12672_2025_3520_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec5"><title>Paraneoplastic neurological syndromes (PNS)</title><p id="Par32">Beyond direct physical invasion, many tumors exert an aberrant immune response, resulting in paraneoplastic neurological syndromes. These syndromes occur when the immune system, while targeting tumor cells, cross-reacts with antigens expressed in the nervous system. Onconeural antibodies such as anti-Hu, anti-Yo, and anti-Ri can cause encephalomyelitis, cerebellar degeneration, or brainstem dysfunction [<xref ref-type="bibr" rid="CR60">60</xref>]. Onconeural antibodies, such as anti-Hu (ANNA-1), anti-Yo (PCA-1), and anti-Ri (ANNA-2), are directed against intracellular neuronal proteins. These antibodies are associated with distinct clinical syndromes: anti-Hu with encephalomyelitis and sensory neuronopathy, anti-Yo with paraneoplastic cerebellar degeneration, and anti-Ri with opsoclonus-myoclonus and brainstem encephalitis [<xref ref-type="bibr" rid="CR12">12</xref>]. Clinically, PNS manifests with rapidly progressive and often multifocal neurological symptoms, including cognitive decline, ataxia, seizures, myoclonus, and autonomic instability. The most frequently associated cancers include small-cell lung carcinoma, breast cancer, ovarian cancer, and Hodgkin lymphoma. Treatment is challenging, as the efficacy of immunosuppressive therapy (e.g., corticosteroids, intravenous immunoglobulin, plasmapheresis, or rituximab) is often limited once irreversible neuronal injury has occurred [<xref ref-type="bibr" rid="CR15">15</xref>]. Despite advances in antibody detection, controversies persist regarding whether all PNS cases are antibody-mediated, as seronegative patients with indistinguishable clinical syndromes remain common. Additionally, prospective studies clarifying the optimal timing, duration, and combination of immunosuppressive therapies are lacking, representing a major research priority. Thus, early recognition and prompt initiation of immunotherapy, in conjunction with oncologic treatment of the primary tumor, are essential for improving prognosis and halting further neurological deterioration.</p></sec><sec id="Sec6"><title>Systemic inflammation and neuroimmune disruption</title><p id="Par33">Inflammation represents another important mechanism of neurophysiological dysfunction in cancer. Many malignancies induce a chronic systemic inflammatory state characterized by overexpression levels of cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-&#945;), and interleukin-1&#946; (IL-1&#946;) and vascular endothelial growth factor (VEGF) [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. These cytokines can penetrate the blood-brain barrier and activate microglia and astrocytes, leading to neuroinflammation and synaptic disruption. Activated microglia and astrocytes in the central nervous system can impair synaptic function, leading to cognitive deficits and other neuropsychiatric manifestations. Even in the absence of direct CNS involvement or chemotherapy, patients can experience fatigue, depression, and cognitive decline [<xref ref-type="bibr" rid="CR16">16</xref>]. Functional neuroimaging studies have demonstrated alterations in hippocampal and prefrontal connectivity in such patients. In cases of cytokine release syndrome, such as during CAR-T cell therapy, inflammation can become acute and severe, resulting in life-threatening encephalopathy [<xref ref-type="bibr" rid="CR68">68</xref>]. Systemic inflammation in cancer exerts profound neuroimmune effects, where elevated cytokines disrupt neural integrity and function. Significant uncertainty remains about the threshold levels and chronicity of cytokine elevation required to cause irreversible neurological damage. Moreover, there is a lack of standardized biomarkers for monitoring neuroimmune disruption across different cancer types, limiting early detection and targeted intervention strategies.</p></sec><sec id="Sec7"><title>Metabolic dysregulation</title><p id="Par34">Metabolic disturbances and cancer treatment regimens can affect neurological complications in oncology patients. Hyponatremia, often linked to the syndrome of improper antidiuretic hormone secretion (SIADH), particularly in small-cell lung cancer, has been associated with seizures and altered mental status [<xref ref-type="bibr" rid="CR46">46</xref>]. Conversely, hypercalcemia resulting from bone metastases can cause symptoms ranging from confusion and lethargy to delirium and coma. Additionally, deficiencies in essential nutrients such as vitamin B12 or folate, especially in patients with hematological or gastrointestinal malignancies, can lead to subacute combined degeneration of the spinal cord, manifesting as weakness, sensory ataxia, and spasticity [<xref ref-type="bibr" rid="CR46">46</xref>]. These metabolic imbalances can further intensify pre-existing neuroinflammation and increase neuronal vulnerability. Although many of these conditions are potentially reversible with timely intervention, they are frequently underdiagnosed. This indicates the importance of routine metabolic screening in cancer patients presenting with neurological symptoms. Early recognition and correction of these imbalances are critical to prevent irreversible neural damage and improve patient outcomes [<xref ref-type="bibr" rid="CR31">31</xref>].</p></sec><sec id="Sec8"><title>Chemotherapy-induced neurotoxicity</title><p id="Par35">Chemotherapy is integral to cancer treatment but carries a significant risk of neurotoxicity, affecting both the peripheral and central nervous systems. The type and severity of neurological complications depend on the specific agent, dosage, and patient susceptibility. Chemotherapeutic agents, including platinum-based compounds such as cisplatin and oxaliplatin, induce neurotoxicity as summarised in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. These compounds have been reported to interfere with DNA-repairing pathways and disrupt mitochondrial function, leading to sensory neuropathies [<xref ref-type="bibr" rid="CR64">64</xref>]. Taxanes (e.g., paclitaxel) and vinca alkaloids (e.g., vincristine) act by destabilizing microtubules and impairing axonal transport, resulting in distal symmetric polyneuropathy, which may be motor, sensory, or mixed. In the central nervous system, agents like 5-fluorouracil (5-FU) have been shown to impair hippocampal neurogenesis. This results in memory loss, attentional deficits, and executive dysfunction collectively known as chemotherapy-related cognitive impairment, or &#8220;chemo brain [<xref ref-type="bibr" rid="CR19">19</xref>]. These neurotoxic effects are dose-dependent and can be amplified in patients with preexisting inflammatory, metabolic, or nutritional vulnerabilities. Electrophysiological assessments frequently demonstrate reduced sensory nerve action potentials and axonal degeneration, while neuroimaging studies reveal white matter changes, reduced connectivity in important brain networks, and functional deficits in prefrontal and hippocampal regions [<xref ref-type="bibr" rid="CR65">65</xref>]. Although multiple chemotherapeutic classes have well-documented neurotoxic profiles, there is considerable interpatient variability in onset, severity, and recovery, suggesting uncharacterized genetic and metabolic modifiers. Research should focus on clarifying the uncharacterized genetic and metabolic factors that influence chemotherapy-induced neurotoxicity.</p><p id="Par36">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Summary of chemotherapy-induced cognitive impairment</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Chemotherapeutic Agent</th><th align="left" colspan="1" rowspan="1">Cognitive Effects</th><th align="left" colspan="1" rowspan="1">Cancer Types Treated</th><th align="left" colspan="1" rowspan="1">Mechanism of Neurotoxicity</th><th align="left" colspan="1" rowspan="1">Site</th><th align="left" colspan="1" rowspan="1">Reversibility</th><th align="left" colspan="1" rowspan="1">Mitigation Strategies</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">5-Fluorouracil (5-FU)</td><td align="left" colspan="1" rowspan="1">Memory loss, impaired learning, reduced hippocampal neurogenesis</td><td align="left" colspan="1" rowspan="1">Colorectal, breast, gastric</td><td align="left" colspan="1" rowspan="1">Inhibits hippocampal neurogenesis</td><td align="left" colspan="1" rowspan="1">CNS</td><td align="left" colspan="1" rowspan="1">Partial</td><td align="left" colspan="1" rowspan="1">Cognitive rehab, rest</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR18">18</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Methotrexate</td><td align="left" colspan="1" rowspan="1">Attention deficits, executive dysfunction, and delayed processing speed</td><td align="left" colspan="1" rowspan="1">Breast, lymphoma, leukemia</td><td align="left" colspan="1" rowspan="1">Folate antagonism, white matter toxicity</td><td align="left" colspan="1" rowspan="1">CNS</td><td align="left" colspan="1" rowspan="1">Partial</td><td align="left" colspan="1" rowspan="1">Leucovorin rescue, dose modulation</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR6">6</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Cisplatin</td><td align="left" colspan="1" rowspan="1">Cognitive slowing, working memory impairment</td><td align="left" colspan="1" rowspan="1">Testicular, ovarian, head, and neck</td><td align="left" colspan="1" rowspan="1">Mitochondrial damage, DNA crosslinking</td><td align="left" colspan="1" rowspan="1">PNS</td><td align="left" colspan="1" rowspan="1">Often irreversible</td><td align="left" colspan="1" rowspan="1">Antioxidants, dose limitation</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR43">43</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Oxaliplatin</td><td align="left" colspan="1" rowspan="1">Executive dysfunction, sensory disturbances</td><td align="left" colspan="1" rowspan="1">Colorectal, gastric, pancreatic</td><td align="left" colspan="1" rowspan="1">Voltage-gated sodium channel dysfunction</td><td align="left" colspan="1" rowspan="1">PNS</td><td align="left" colspan="1" rowspan="1">Partial</td><td align="left" colspan="1" rowspan="1">Calcium/magnesium infusions</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR10">10</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Cyclophosphamide</td><td align="left" colspan="1" rowspan="1">Reduced attention and verbal fluency</td><td align="left" colspan="1" rowspan="1">Breast, lymphoma</td><td align="left" colspan="1" rowspan="1">Oxidative stress, cytokine release</td><td align="left" colspan="1" rowspan="1">CNS</td><td align="left" colspan="1" rowspan="1">Partial</td><td align="left" colspan="1" rowspan="1">Hydration, antioxidant support</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR25">25</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Doxorubicin</td><td align="left" colspan="1" rowspan="1">Visual memory deficits, impaired executive function</td><td align="left" colspan="1" rowspan="1">Breast, sarcoma</td><td align="left" colspan="1" rowspan="1">Oxidative damage, mitochondrial dysfunction</td><td align="left" colspan="1" rowspan="1">CNS</td><td align="left" colspan="1" rowspan="1">Partial</td><td align="left" colspan="1" rowspan="1">Neuroprotective agents under study</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Paclitaxel</td><td align="left" colspan="1" rowspan="1">Short-term memory loss, reduced psychomotor speed</td><td align="left" colspan="1" rowspan="1">Breast, ovarian, lung</td><td align="left" colspan="1" rowspan="1">Microtubule destabilization</td><td align="left" colspan="1" rowspan="1">PNS</td><td align="left" colspan="1" rowspan="1">Partial</td><td align="left" colspan="1" rowspan="1">Duloxetine, vitamin B supplementation</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR13">13</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Ifosfamide</td><td align="left" colspan="1" rowspan="1">Confusion, encephalopathy (especially at high doses)</td><td align="left" colspan="1" rowspan="1">Sarcoma, lymphoma</td><td align="left" colspan="1" rowspan="1">Chloracetaldehyde metabolite neurotoxicity</td><td align="left" colspan="1" rowspan="1">CNS</td><td align="left" colspan="1" rowspan="1">Reversible (early)</td><td align="left" colspan="1" rowspan="1">Methylene blue, hydration</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec9"><title>Radiation-induced CNS injury</title><p id="Par37">Radiotherapy represents the cornerstone in the management of central nervous system malignancies, yet its therapeutic benefits are often offset by the risk of radiation-induced neurotoxicity. The brain and spinal cord are particularly susceptible due to their limited capacity for repair. Radiotherapy, when directed at the brain or spinal cord, can result in delayed-onset neurotoxicity due to complex mechanisms involving vascular injury, demyelination, and tissue necrosis. The central nervous system is particularly vulnerable to radiation-induced damage because of its limited regenerative capacity. Whole-brain radiotherapy (WBRT), commonly used in treating brain metastases, has been strongly associated with progressive cognitive decline, white matter atrophy, and executive dysfunction, particularly in pediatric and elderly populations [<xref ref-type="bibr" rid="CR41">41</xref>]. The pathophysiology of radiation-induced CNS injury includes endothelial cell damage, which compromises the blood&#8211;brain barrier, leading to vasogenic edema, microhemorrhages, and cerebral hypoxia. In parallel, chronic neuroinflammation, oxidative stress, and inhibition of neurogenesis, especially in hippocampal regions, contribute to long-term functional impairment. Demyelination occurs due to damage to oligodendrocytes, further impairing neuronal conduction [<xref ref-type="bibr" rid="CR9">9</xref>]. Radiation effects can be classified into acute (within days to weeks), early-delayed (within 1&#8211;6 months), and late-delayed (after 6 months to years) phases. Late effects are often the most debilitating, with symptoms including memory loss, attention deficits, gait disturbances, and in severe cases, radiation necrosis or leukoencephalopathy. Notably, MRI findings in these patients may mimic tumor recurrence, showing contrast enhancement and mass effect, which can lead to diagnostic uncertainty and mismanagement. Timely recognition, accurate diagnosis, and preventive strategies are essential to minimize long-term functional impairment.</p></sec><sec id="Sec10"><title>Immune checkpoint inhibitor (ICI)-associated neurotoxicity</title><p id="Par38">The advent of immune checkpoint inhibitors (ICIs) has transformed cancer therapy but introduced new challenges in the form of immune-related neurological adverse events. However, their use has also introduced a spectrum of immune-related adverse events (irAEs), including neurological toxicities, which pose diagnostic and therapeutic challenges. Neurological irAEs, though less common than dermatologic or gastrointestinal ones, can be serious and potentially life-threatening, occurring in approximately 1&#8211;4% of patients receiving ICIs [<xref ref-type="bibr" rid="CR66">66</xref>]. Reported manifestations include autoimmune encephalitis, aseptic meningitis, myositis, Guillain&#8211;Barr&#233;-like syndromes, and demyelinating polyneuropathies. These complications are often misdiagnosed and underrecognized, especially when they mimic tumor progression, paraneoplastic syndromes, or infections. Clinical presentations may range from mild sensory disturbances and fatigue to rapidly progressive motor deficits, seizures, or altered mental status [<xref ref-type="bibr" rid="CR24">24</xref>]. Tumor- and therapy-induced neurological dysfunction arises from a complex interplay of direct invasion, immune cross-reactivity, vascular compromise, and treatment-related toxicity. A mechanistic understanding is essential for guiding both diagnostic evaluation and targeted intervention.</p></sec></sec><sec id="Sec11"><title>Neurological implications of commonly occurring cancers</title><p id="Par39">The nervous system is vulnerable to injury in many systemic malignancies through three principal mechanisms, including direct tumor invasion or compression, immune-mediated (paraneoplastic) complications, and treatment-induced neurotoxicity. Table&#160;<xref rid="Tab2" ref-type="table">2</xref> provides a comprehensive summary of the specific mechanisms and clinical manifestations of neurological dysfunction associated with various cancer types. Lung cancer, particularly small-cell lung carcinoma (SCLC), is the prototypical malignancy associated with paraneoplastic neurological syndromes (PNS). These immune-mediated disorders, including paraneoplastic encephalomyelitis and Lambert-Eaton myasthenic syndrome, reflect neural damage secondary to anti-neuronal antibodies triggered by tumor antigens. SCLC is clinically relevant due to its high rate of brain metastases and diagnostic challenge. In such cases, early detection of paraneoplastic antibodies and prompt imaging are important for preventing irreversible deficits [<xref ref-type="bibr" rid="CR61">61</xref>]. Breast cancer, particularly HER2-positive and triple-negative subtypes, demonstrates a marked predilection for central nervous system metastases. These metastases are often poorly penetrated by systemic therapies due to the blood-brain barrier, resulting in a therapeutic sanctuary site. Moreover, chemotherapy-induced peripheral neuropathy, especially from taxanes or platinum agents, contributes to long-term morbidity even in remission [<xref ref-type="bibr" rid="CR72">72</xref>]. Prostate cancer&#8217;s neurological relevance is often underestimated. While direct CNS metastasis is rare, epidural spinal cord compression from vertebral involvement is a medical emergency. Clinicians must maintain a high index of suspicion when patients present with new-onset back pain, motor weakness, or bladder dysfunction. Early MRI and prompt corticosteroid initiation followed by surgical or radiological decompression can be life-altering interventions [<xref ref-type="bibr" rid="CR47">47</xref>]. Colorectal cancer and melanoma offer contrasting neurological profiles. Colorectal cancer rarely invades the CNS directly, yet oxaliplatin-induced neuropathy remains a major dose-limiting toxicity [<xref ref-type="bibr" rid="CR11">11</xref>]. Melanoma, in contrast, has a high affinity for brain tissue and is often complicated by hemorrhagic metastases. The advent of immune checkpoint inhibitors has improved survival but also introduced new neurological syndromes such as autoimmune encephalitis and hypophysitis. These cases demand close monitoring and nuanced immunosuppressive management [<xref ref-type="bibr" rid="CR63">63</xref>]. Additionally, hematological malignancies such as acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma frequently involve the CNS either at diagnosis or during relapse. Intrathecal chemotherapy and cranial irradiation are standard prophylactic strategies but come with neurodevelopmental risks in pediatric populations and cognitive sequelae in adults [<xref ref-type="bibr" rid="CR42">42</xref>]. Different cancers type cause different neurological dysfunction, making early detection and management important to preserve neurological function and improve quality of life.</p><p id="Par40">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Neurological implications of selected high-incidence cancers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Cancer Type (common subtype)</th><th align="left" colspan="1" rowspan="1">Principal mechanism(s) of neural injury</th><th align="left" colspan="1" rowspan="1">Typical neurological manifestations</th><th align="left" colspan="1" rowspan="1">Key diagnostic tools</th><th align="left" colspan="1" rowspan="1">First-line management/preventive actions</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Lung &#8211; Small-cell carcinoma (SCLC)</td><td align="left" colspan="1" rowspan="1"><p>Paraneoplastic autoimmunity (anti-Hu, CV2, etc.)</p><p>Early &amp; frequent brain metastasis</p></td><td align="left" colspan="1" rowspan="1"><p>Paraneoplastic encephalomyelitis</p><p>Lambert-Eaton myasthenic syndrome (LEMS)</p><p>Seizures, focal deficits from brain mets</p></td><td align="left" colspan="1" rowspan="1"><p>Serum / CSF onco-neuronal antibodies</p><p>Contrast brain MRI / PET</p></td><td align="left" colspan="1" rowspan="1"><p>Prompt immunotherapy (IV steroids, IVIg, plasma exchange)</p><p>Systemic&#8201;&#177;&#8201;CNS-penetrant chemotherapy</p><p>Prophylactic or therapeutic cranial radiotherapy</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Breast &#8211; HER2+ &amp; triple-negative</td><td align="left" colspan="1" rowspan="1"><p>Hematogenous brain metastasis (therapeutic &#8220;sanctuary&#8221;)</p><p>Taxane/platinum chemotherapy-induced peripheral neuropathy (CIPN)</p></td><td align="left" colspan="1" rowspan="1"><p>Headache, seizures, focal deficits</p><p>Stocking-glove sensory loss, neuropathic pain</p></td><td align="left" colspan="1" rowspan="1"><p>Gadolinium brain MRI&#8201;&#177;&#8201;PET-MRI</p><p>Nerve conduction studies / Neuropathy scores</p></td><td align="left" colspan="1" rowspan="1"><p>SRS/SBRT or CNS-active HER2 therapy (e.g., tucatinib)</p><p>CIPN mitigation (cryotherapy, duloxetine, dose modification)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Prostate (metastatic)</td><td align="left" colspan="1" rowspan="1">Vertebral metastasis Epidural spinal-cord compression (ESCC)</td><td align="left" colspan="1" rowspan="1"><p>New-onset back pain</p><p>Paraparesis/quadriparesis</p><p>Bladder/bowel dysfunction</p></td><td align="left" colspan="1" rowspan="1">Urgent whole-spine MRI</td><td align="left" colspan="1" rowspan="1"><p>High-dose dexamethasone</p><p>Surgical decompression or urgent radiotherapy</p><p>Early urologic/neurosurgical consultation</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Colorectal</td><td align="left" colspan="1" rowspan="1"><p>Oxaliplatin-induced &#8594; sensory neuropathy</p><p>(Rare) brain metastases</p></td><td align="left" colspan="1" rowspan="1"><p>Cold-triggered paranesthesia</p><p>Persistent stocking-glove numbness, gait imbalance</p></td><td align="left" colspan="1" rowspan="1"><p>Clinical Total Neuropathy Score</p><p>Quantitative sensory testing</p></td><td align="left" colspan="1" rowspan="1"><p>Infusion-time adjustment/dose reduction</p><p>Calcium and magnesium infusion, duloxetine</p><p>Patient education on cold avoidance</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1"><p>Hemorrhagic brain metastasis</p><p>Immune checkpoint inhibitor (ICI)-related neurotoxicity (autoimmune encephalitis, hypophysitis)</p></td><td align="left" colspan="1" rowspan="1"><p>Acute intracranial bleed &#8594; headache, seizures</p><p>Memory loss, pituitary insufficiency</p></td><td align="left" colspan="1" rowspan="1"><p>MRI with susceptibility-weighted imaging (SWI) for hemorrhage</p><p>Pituitary panel; CSF / autoantibody screen</p></td><td align="left" colspan="1" rowspan="1"><p>Neurosurgery / SRS for hemorrhages</p><p>High-dose steroids&#8201;&#177;&#8201;IVIg for ICI adverse events</p><p>Endocrine replacement therapy</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Haematologic &#8211; ALL, NHL</td><td align="left" colspan="1" rowspan="1"><p>Leukemic/lymphomatous CNS infiltration</p><p>Neurotoxic intrathecal chemotherapy &amp; cranial radiotherapy</p></td><td align="left" colspan="1" rowspan="1"><p>Meningeal signs, cranial nerve palsies</p><p>Long-term cognitive decline (children&#8201;&gt;&#8201;adults)</p></td><td align="left" colspan="1" rowspan="1"><p>CSF cytology/flow cytometry</p><p>Brain &amp; spine MRI</p><p>Neuropsychological testing</p></td><td align="left" colspan="1" rowspan="1"><p>Scheduled intrathecal methotrexate&#8201;&#177;&#8201;systemic high-dose methotrexate</p><p>Radiotherapy dose-sparing protocols</p><p>Serial neurocognitive monitoring</p></td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec12"><title>Therapeutic strategies and interventions</title><p id="Par41">Treatment of cancer-related neurological complications is guided by four core objectives: alleviating symptoms, protecting neural tissue from further damage, and restoring neurological function through rehabilitation, as depicted by Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>. Symptomatic management remains the cornerstone of clinical intervention for many cancer-related neurological complications [<xref ref-type="bibr" rid="CR22">22</xref>]. Pharmacologic therapies are commonly used to control seizures, neuropathic pain, spasticity, and mooddisorders. Anticonvulsants such as levetiracetam and valproate are employed in patients with brain tumors or metastases, while neuropathic pain resulting from chemotherapy-induced peripheral neuropathy is managed with agents like gabapentin, pregabalin, or duloxetine [<xref ref-type="bibr" rid="CR8">8</xref>]. Corticosteroids can be administered to reduce tumor-associated edema and relieve pressure symptoms, although long-term use is limited by systemic side effects. In cases of paraneoplastic syndromes, immunosuppressive therapies including intravenous immunoglobulin (IVIG), plasmapheresis, or corticosteroids can help mitigate immune-mediated neuronal injury [<xref ref-type="bibr" rid="CR36">36</xref>]. Beyond symptom control, a growing focus is being placed on neuroprotective interventions aimed at preserving neuronal integrity and function during cancer treatment. Several agents, such as amifostine, have shown potential in protecting against radiation-induced neurotoxicity, while other compounds targeting oxidative stress and mitochondrial dysfunction are under investigation. Nutraceuticals and dietary supplements, including omega-3 fatty acids, curcumin, and antioxidants, are also being explored for their neuroprotective properties, though robust clinical evidence remains limited [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. Furthermore, neurorehabilitation also plays an important role in restoring function and improving quality of life. Multidisciplinary rehabilitation programs that incorporate physical therapy, occupational therapy, speech-language therapy, and cognitive training are essential, particularly for patients recovering from brain tumors or experiencing treatment-induced cognitive impairment [<xref ref-type="bibr" rid="CR51">51</xref>]. Cognitive remediation techniques, often delivered through computerized platforms, have demonstrated improvements in attention, memory, and executive function, especially in cancer survivors with mild to moderate deficits. Neuromodulation technologies are emerging as promising adjuncts in the management of cancer-related neurological dysfunction [<xref ref-type="bibr" rid="CR37">37</xref>]. Non-invasive brain stimulation techniques, such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), have shown potential in improving cognitive function and alleviating depressive symptoms in cancer patients. These approaches modulate cortical excitability and neural plasticity and are being increasingly integrated into neuro-oncological care frameworks. An area of growing interest is the development of therapies that target the tumor-immune-neural axis. Advances in immunotherapy have improved both therapeutic potential and neurotoxic risks, necessitating a careful balance between oncologic efficacy and neurological safety [<xref ref-type="bibr" rid="CR21">21</xref>]. Investigational treatments focusing on modulating neuroinflammation, restoring blood-brain barrier integrity, or enhancing neurogenesis represent the next frontier in neuroprotective oncology. Finally, personalized medicine approaches are being explored to optimize therapy selection based on genetic, molecular, and neurophysiological profiles [<xref ref-type="bibr" rid="CR40">40</xref>]. Effective management of cancer-related neurological dysfunction requires early recognition, multidisciplinary intervention, and long-term monitoring. Tailoring therapy to the underlying mechanism, whether immune, metabolic, or structural, can improve patient outcomes and reduce chronic morbidity.</p><p id="Par42">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Therapeutic strategies and interventions of tumor-induced neurological. This schematic illustrates the multidimensional therapeutic approach to managing neurological complications arising from tumor growth within the central nervous system (CNS). Tumor mass effect leads to direct compression of neural structures, resulting in cognitive and functional deficits. Immunotherapeutic strategies, including T cell&#8211;mediated cytotoxicity and monoclonal antibody-based interventions, aim to restore antitumor immune responses and target malignant cells. Pharmacological agents mitigate neuroinflammation and associated symptoms, while rehabilitative interventions support the recovery of neurological function and enhance quality of life</p></caption><graphic id="d33e918" position="float" orientation="portrait" xlink:href="12672_2025_3520_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec13"><title>Role of neurodiagnostic tools in assessing neurophysiological alterations in cancer</title><p id="Par43">Accurate assessment of neurophysiological alterations in cancer requires an integrated diagnostic approach that captures structural, functional, metabolic, and real-time physiological changes. The neurodiagnostic modalities discussed in the subsequent sections highlight the complementary contributions of imaging, electrophysiological techniques, metabolic profiling, and emerging wearable technologies. Additionally, Table&#160;<xref rid="Tab3" ref-type="table">3</xref> provides a consolidated overview of these neurodiagnostic tools, detailing their diagnostic roles, clinical utility, advantages, and limitations. Providing a practical reference for clinicians and researchers aiming to optimize diagnostic accuracy while balancing feasibility, patient safety, and resource availability.</p><p id="Par44">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Neurodiagnostic tools in assessing neurophysiological alterations in cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Tool / modality</th><th align="left" colspan="1" rowspan="1">Diagnostic role</th><th align="left" colspan="1" rowspan="1">Clinical utility</th><th align="left" colspan="1" rowspan="1">Advantages</th><th align="left" colspan="1" rowspan="1">Disadvantages</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Magnetic Resonance Imaging (MRI) / fMRI</td><td align="left" colspan="1" rowspan="1">Structural and functional imaging detects tumor infiltration, edema, necrosis, and functional disruptions in cognitive networks.</td><td align="left" colspan="1" rowspan="1">Essential for diagnosis, treatment planning, and monitoring treatment response.</td><td align="left" colspan="1" rowspan="1">High-resolution imaging; non-invasive; excellent for structural and functional assessment.</td><td align="left" colspan="1" rowspan="1">Expensive; limited availability in low-resource settings; contraindicated in some implants.</td></tr><tr><td align="left" colspan="1" rowspan="1">Diffusion Tensor Imaging (DTI)</td><td align="left" colspan="1" rowspan="1">Assesses microstructural white matter integrity; detects axonal damage and demyelination early.</td><td align="left" colspan="1" rowspan="1">Guides rehabilitation strategies and tracks the progression of white matter injury.</td><td align="left" colspan="1" rowspan="1">Sensitive to early white matter changes; useful in cognitive impairment studies.</td><td align="left" colspan="1" rowspan="1">Susceptible to motion artifacts; requires technical expertise for interpretation.</td></tr><tr><td align="left" colspan="1" rowspan="1">Electroencephalography (EEG)</td><td align="left" colspan="1" rowspan="1">Real-time assessment of cortical function; detects seizures, encephalopathies, and paraneoplastic effects.</td><td align="left" colspan="1" rowspan="1">Informs management of seizures and neurologic complications; supports early intervention.</td><td align="left" colspan="1" rowspan="1">Portable; excellent temporal resolution; useful in seizure detection.</td><td align="left" colspan="1" rowspan="1">Low spatial resolution; may miss deep brain abnormalities.</td></tr><tr><td align="left" colspan="1" rowspan="1">Positron Emission Tomography (PET) / PET-MRI</td><td align="left" colspan="1" rowspan="1">Provides metabolic and molecular data; differentiates tumor recurrence from necrosis, detects low-grade gliomas.</td><td align="left" colspan="1" rowspan="1">Improves localization and specificity in recurrent or complex cases.</td><td align="left" colspan="1" rowspan="1">Combines functional and anatomical data; distinguishes tumor recurrence from necrosis.</td><td align="left" colspan="1" rowspan="1">High cost; limited access; requires radioactive tracers.</td></tr><tr><td align="left" colspan="1" rowspan="1">Digital and Wearable Technologies</td><td align="left" colspan="1" rowspan="1">Tracks cognitive, motor, and autonomic functions continuously; supports remote monitoring and early detection of late neurotoxicity.</td><td align="left" colspan="1" rowspan="1">Facilitates survivorship care and enhances patient adherence to neurorehabilitation.</td><td align="left" colspan="1" rowspan="1">Continuous and remote monitoring supports real-time data collection and patient engagement.</td><td align="left" colspan="1" rowspan="1">Data interpretation requires validation; privacy concerns with continuous monitoring.</td></tr></tbody></table></table-wrap>
</p><sec id="Sec14"><title>Magnetic resonance imaging (MRI) and functional MRI (fMRI)</title><p id="Par45">MRI remains the gold standard for detecting structural abnormalities in the brain and spinal cord. It is used to detect tumor infiltration, peritumoral edema, necrosis, hemorrhage, and post-treatment changes. Advanced MRI techniques, such as contrast-enhanced T1-weighted imaging and FLAIR sequences, are essential in differentiating tumor recurrence from radiation necrosis. Functional MRI (fMRI) enables visualization of brain activity and neural connectivity, making it an important tool in mapping eloquent cortex areas before surgical intervention. fMRI can detect changes in cognitive networks in patients experiencing chemotherapy-related cognitive impairment, offering insights into functional disruptions not visible on standard MRI [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. MRI and fMRI offer real-time assessment of structural and functional brain alterations as depicted in Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>. However, there is ongoing debate regarding the reproducibility of fMRI connectivity metrics in cancer populations and whether observed changes reliably correlate with long-term cognitive outcomes. Furthermore, robust longitudinal datasets linking imaging biomarkers to patient-centered functional recovery are lacking. Overall, MRI and fMRI provide unparalleled structural and functional insights. Advancing their clinical value will require longitudinal studies that directly connect imaging biomarkers with meaningful functional recovery and quality-of-life outcomes in cancer patients.</p><p id="Par46">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Diagnostic approaches for detecting central nervous system involvement in cancer. The figure illustrates the multimodal diagnostic strategies used to detect cancer-related pathologies within the central nervous system (CNS). Techniques include cerebrospinal fluid (CSF) analysis for identifying inflammation or tumor cells, detection of circulating tumor DNA (ctDNA) in CSF for tumor-specific mutations, assessment of onconeural antibodies as biomarkers, and imaging tools such as MRI and PET for visualizing leptomeningeal metastases</p></caption><graphic id="d33e1030" position="float" orientation="portrait" xlink:href="12672_2025_3520_Fig3_HTML.jpg"/></fig>
</p></sec><sec id="Sec15"><title>Diffusion tensor imaging (DTI)</title><p id="Par47">DTI is an important modality technique for assessing the microstructural integrity of white matter tracts. It measures fractional anisotropy and mean diffusivity, providing early detection of axonal injury and demyelination. This is particularly useful in patients exposed to neurotoxic chemotherapy or cranial radiation. DTI abnormalities correlate with deficits in memory, attention, and executive function, and can guide rehabilitation strategies [<xref ref-type="bibr" rid="CR56">56</xref>]. Current limitations include (i) large inter-site variability in acquisition parameters (e.g., b-values, gradient directions), (ii) heterogeneous post-processing pipelines, and (iii) the absence of age- and sex-stratified normative datasets. Additionally, no prospective trial has yet demonstrated that modifying or de-escalating cancer therapy based on early DTI changes improves long-term neurological outcomes or oncologic control. Addressing this translational gap will require harmonised imaging protocols, multi-centre biobanks of raw diffusion data, and interventional studies that test DTI-guided treatment adaptation.</p></sec><sec id="Sec16"><title>Electroencephalography (EEG) and evoked potentials</title><p id="Par48">EEG offers a real-time assessment of electrical activity in the brain. It is important in diagnosing seizures, encephalopathies, and paraneoplastic syndromes. In patients with altered mental status or cognitive decline, EEG can reveal cortical slowing, epileptiform discharges, or nonconvulsive seizures [<xref ref-type="bibr" rid="CR52">52</xref>]. Evoked potentials visual (VEP), auditory (BAEP), and somatosensory (SSEP) are useful in detecting subclinical impairments in sensory pathways. These tests can identify early demyelination or conduction delays in patients with paraneoplastic syndromes or radiation-induced damage, often before clinical symptoms emerge [<xref ref-type="bibr" rid="CR35">35</xref>]. Controversies exist about the specificity of EEG and evoked potential abnormalities in cancer patients, as similar patterns may arise from metabolic disturbances, infections, or treatment side effects. Additionally, large-scale studies validating prognostic cut-offs for these electrophysiological findings in oncology settings are lacking. Future research should prioritize standardizing electrophysiological interpretation criteria for oncology populations, developing disease-specific normative databases, and integrating EEG/evoked potential metrics with imaging and biomarker data to enhance diagnostic precision and prognostic value.</p></sec><sec id="Sec17"><title>Positron emission tomography (PET) and PET-MRI</title><p id="Par49">PET imaging complements anatomical studies by offering metabolic and molecular insights. 18&#160;F-FDG PET detects hypermetabolic tumor foci, differentiates viable tumor from necrosis, and assesses systemic metastatic spread. PET-MRI combines metabolic and high-resolution anatomical data, providing superior localization and specificity in evaluating complex neuro-oncological cases. Novel radiotracers targeting amino acid metabolism or tumor-specific receptors enhance PET&#8217;s diagnostic accuracy, particularly in identifying low-grade gliomas or early recurrence [<xref ref-type="bibr" rid="CR3">3</xref>]. Despite these strengths, PET imaging remains constrained by limited availability, high radiation exposure, and uncertainty about the added prognostic value of newer tracers in routine practice. Moreover, comparative trials between PET-MRI and advanced MRI alone for cost-effectiveness and outcome prediction are scarce. Future priorities include protocol harmonisation, multicentre cost-utility analyses, and prospective studies testing PET-guided adaptive therapies.</p></sec><sec id="Sec18"><title>Emerging digital and wearable technologies</title><p id="Par50">Recent advancements in digital health tools have enabled continuous, non-invasive monitoring of neurological function. Wearable EEG devices, accelerometers, and biosensors track cognitive activity, sleep patterns, gait stability, and autonomic parameters in real time. These tools are especially beneficial in survivorship programs and rural settings where access to frequent clinical evaluation is limited. Artificial intelligence algorithms integrated with these devices can analyze large datasets to predict neurological decline and guide timely interventions. Their use also fosters patient engagement and adherence to neurorehabilitation protocols. The clinical adoption of wearable neurodiagnostic devices is limited by a lack of regulatory consensus, limited validation in diverse cancer populations, and uncertainties about data privacy and integration into existing healthcare systems. Longitudinal studies are needed to determine whether continuous monitoring improves survival or quality-of-life outcomes in cancer survivors.</p></sec></sec><sec id="Sec19"><title>Emerging biomarkers in neurophysiological alterations in cancer</title><p id="Par51">As the field of neuro-oncology advances, there is growing interest in the development of novel biomarkers that can detect neurological dysfunction at a subclinical stage. This is key in predicting treatment-related neurotoxicity and guides personalized therapeutic interventions. One important group of biomarkers includes onconeural antibodies, such as anti-Hu, anti-Yo, anti-Ri, and anti-Ma. These antibodies are associated with paraneoplastic neurological syndrome conditions where the immune system, in targeting cancer cells, mistakenly attacks neurons [<xref ref-type="bibr" rid="CR20">20</xref>]. Their presence in blood or cerebrospinal fluid (CSF) is often an early signal of an underlying malignancy and can appear before the cancer itself is diagnosed. Clinically, detecting these antibodies helps initiate early immunotherapy and reduces the risk of irreversible neurological damage [<xref ref-type="bibr" rid="CR58">58</xref>]. Another promising marker is neurofilament light chain (NfL), a structural protein released during axonal injury. Elevated levels of NfL in the blood or CSF have been reported in patients undergoing chemotherapy or radiation, particularly those developing peripheral neuropathy or cognitive impairment. Because it can be measured non-invasively through blood tests, NfL is well-suited for long-term monitoring of patients at risk of neurotoxicity [<xref ref-type="bibr" rid="CR69">69</xref>]. Markers from glial cells, such as glial fibrillary acidic protein (GFAP) and S100B, have recently been used. GFAP is an astrocytic protein released during glial damage, such as that caused by radiation therapy or brain tumors. S100B, another glial protein, is associated with blood-brain barrier disruption and early-stage neuroinflammation. Both markers provide useful information about central nervous system integrity and help differentiate between tumor-related and treatment-related neurological symptoms [<xref ref-type="bibr" rid="CR34">34</xref>]. On the genetic and molecular side, circulating tumor DNA (ctDNA) offers a non-invasive method to detect tumor-derived mutations. When extracted from CSF, ctDNA can reveal the presence of central nervous system involvement, including brain metastases and leptomeningeal disease, with higher sensitivity than plasma. It also enables real-time monitoring of treatment response and detection of drug resistance [<xref ref-type="bibr" rid="CR58">58</xref>]. In addition, microRNAs (miRNAs), small non-coding RNA molecules that regulate gene expression, are emerging as diagnostic and prognostic tools. Changes in specific miRNAs, such as miR-21 and miR-155, have been linked to tumor growth, inflammation, and neuronal stress. Their stability in blood and CSF makes them practical candidates for early detection of cancer-associated neurological complications [<xref ref-type="bibr" rid="CR14">14</xref>]. Furthermore, the introduction of biomarkers has been proven to be important in the field of neuro-oncology, despite the majority remain in the exploratory or early validation phases. Biomarkers like neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and S100B are showing promise for detecting neural injury. For example, while elevated NfL levels correlate with axonal damage in patients receiving chemotherapy or radiation, normative thresholds for clinical decision-making are still being defined, and large-scale prospective validation is lacking [<xref ref-type="bibr" rid="CR70">70</xref>]. Similarly, GFAP and S100B can reflect glial damage and blood-brain barrier disruption, but their specificity is limited, and their use outside of research settings is not yet standardized. At present, these biomarkers are best viewed as adjunctive tools for monitoring, rather than standalone diagnostic criteria [<xref ref-type="bibr" rid="CR1">1</xref>]. Despite this promise, controversies persist regarding the clinical utility of many emerging biomarkers, particularly their ability to distinguish between cancer-related and treatment-induced injury. A lack of consensus on cut-off values, limited multi-center validation, and variability in assay sensitivity hinder their adoption into routine clinical workflows. Moreover, there is a gap in longitudinal studies linking biomarker fluctuations to meaningful neurological and quality-of-life outcomes. Until these issues are addressed, most biomarkers remain adjunctive tools rather than definitive diagnostic standards in neuro-oncology</p></sec><sec id="Sec20"><title>Clinical and translational implications</title><p id="Par52">The growing understanding of tumor-induced neurophysiological alterations carries important clinical and translational implications, reshaping strategies in cancer care. Clinically, the integration of routine neurological assessments into oncology practice is important for detecting subclinical dysfunction early and preventing irreversible damage. This is particularly relevant for patients receiving neurotoxic therapies or presenting with cognitive, sensory, or motor symptoms, who may benefit from baseline and serial neurocognitive as well as neurophysiological evaluations [<xref ref-type="bibr" rid="CR32">32</xref>]. In patients with brain tumors, continuous monitoring of seizure activity, cognitive performance, and motor skills can inform timely adjustments to treatment plans, thereby preserving functional independence. Beyond symptom management, advances in understanding the role of systemic inflammation, autoimmunity, and oxidative stress in cancer-related neurological dysfunction have catalyzed the development of novel therapeutic strategies. These include the use of anti-inflammatory agents, immunomodulators, and antioxidants as potential adjuncts in neuro-oncology. This treatment regimen has been developed to mitigate neurological decline and improve quality of life and treatment tolerance among cancer patients [<xref ref-type="bibr" rid="CR54">54</xref>]. Additionally, research into the tumor&#8211;immune&#8211;neural axis has opened new ways for designing therapies that modulate immune responses while preserving neural integrity. This is a particularly important consideration in the context of immunotherapy-associated neurotoxicity [<xref ref-type="bibr" rid="CR48">48</xref>]. The identification of biomarkers alongside the application of advanced diagnostic tools such as functional imaging and electrophysiology has transformed neuro-oncology. These tools facilitate patient stratification based on neurological risk profiles, enabling more individualized treatment strategies. For example, patients at high risk of chemotherapy-induced neuropathy can benefit from prophylactic interventions or alternative regimens [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. Despite these advances, significant research gaps persist, particularly the lack of standardized protocols and robust evidence from well-designed clinical trials to guide the use of neuroprotective agents [<xref ref-type="bibr" rid="CR17">17</xref>]. Future investigations should prioritize the validation of predictive biomarkers through rigorous comparative trials evaluating neuroprotective interventions. Parallel efforts are needed to develop and implement standardized tools for routine neurocognitive screening across oncology settings. Closing these gaps will be critical for translating mechanistic insights into personalized, proactive neuro-oncological care that optimizes both functional outcomes and quality of life</p></sec><sec id="Sec21"><title>Emerging frontiers in neuromodulation and neuro-oncological monitoring</title><p id="Par53">In recent years, neuromodulation has emerged as a promising therapeutic adjunct for managing cancer-related neurological dysfunction. Non-invasive techniques such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) have demonstrated potential in modulating neural activity to alleviate cognitive and emotional symptoms. Alongside these, invasive neuromodulation technologies are gaining traction due to their ability to provide more precise and sustained regulation of neural circuits [<xref ref-type="bibr" rid="CR27">27</xref>]. One notable advancement is closed-loop deep brain stimulation (DBS), which allows real-time adjustment of stimulation parameters based on neurophysiological feedback. While DBS is well-established for treating movement disorders and epilepsy, its application in oncology is being explored, particularly for addressing cancer-related depression, cognitive fatigue, and seizure control. Closed-loop DBS offers a tailored approach to symptom management by dynamically responding to abnormal cortical rhythms. Vagus nerve stimulation (VNS) is another neuromodulatory technique with emerging relevance in neuro-oncology. Traditionally used in drug-resistant epilepsy and major depressive disorder, VNS influences neuroinflammatory pathways and autonomic nervous system regulation. Preclinical studies suggest that VNS may reduce neuroinflammation and enhance neuroplasticity, making it a potential adjunct therapy for cancer patients suffering from cognitive and mood disturbances [<xref ref-type="bibr" rid="CR39">39</xref>]. Together, these emerging neuromodulation strategies highlight a shift toward precision neuro-oncology, where continuous monitoring and targeted neural circuit modulation</p></sec><sec id="Sec22"><title>Conclusion</title><p id="Par54">Cancer-related neurological dysfunction is a multifactorial phenomenon arising from direct tumor effects, systemic inflammation, metabolic disturbances, and treatment-induced neurotoxicity. These mechanisms converge to disrupt structural integrity, neural connectivity, and cognitive performance, ultimately impairing quality of life and functional independence. Current evidences are complicated by heterogeneous study designs, small sample sizes, and variability in diagnostic criteria factors, which contribute to ongoing controversies. This includes reversibility of chemotherapy-related cognitive impairment, the predictive validity of emerging biomarkers like neurofilament light chain (NfL), and the optimal timing for neuroprotective interventions. An integrative, multidisciplinary approach is essential, incorporating oncologists, neurologists, neuropsychologists, and rehabilitation specialists to ensure early recognition and targeted management. Routine cognitive and neurological screening, combined with personalized intervention strategies, should become a standard component of cancer care pathways. Future research should prioritize large-scale, longitudinal studies that integrate multi-modal neuroimaging, electrophysiology, and biomarker profiling to map the trajectory. Randomized controlled trials are needed to evaluate neuroprotective strategies ranging from anti-inflammatory agents to non-invasive neuromodulation. Furthermore, the Standardization of outcome measurement will improve cross-study comparability and clarify unresolved debates, such as whether neuroinflammatory changes precede measurable cognitive decline. Finally, translational efforts should focus on validating biomarkers for clinical decision-making and developing predictive models to identify high-risk patients early, enabling timely, precision-guided interventions</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>BBB</term><def><p id="Par10">Blood-Brain Barrier</p></def></def-item><def-item><term>CIPN</term><def><p id="Par11">Chemotherapy-Induced Peripheral Neuropathy</p></def></def-item><def-item><term>CNS</term><def><p id="Par12">Central Nervous System</p></def></def-item><def-item><term>CRCI</term><def><p id="Par13">Cancer-Related Cognitive Impairment</p></def></def-item><def-item><term>CSF</term><def><p id="Par14">Cerebrospinal Fluid</p></def></def-item><def-item><term>DTI</term><def><p id="Par15">Diffusion Tensor Imaging</p></def></def-item><def-item><term>EEG</term><def><p id="Par16">Electroencephalography</p></def></def-item><def-item><term>EMG</term><def><p id="Par17">Electromyography</p></def></def-item><def-item><term>fMRI</term><def><p id="Par18">Functional Magnetic Resonance Imaging</p></def></def-item><def-item><term>ICIs</term><def><p id="Par19">Immune Checkpoint Inhibitors</p></def></def-item><def-item><term>MEG</term><def><p id="Par20">Magnetoencephalography</p></def></def-item><def-item><term>MRI</term><def><p id="Par21">Magnetic Resonance Imaging</p></def></def-item><def-item><term>PNS</term><def><p id="Par22">Paraneoplastic Neurological Syndromes</p></def></def-item><def-item><term>PET</term><def><p id="Par23">Positron Emission Tomography</p></def></def-item><def-item><term>qEEG</term><def><p id="Par24">Quantitative Electroencephalography</p></def></def-item><def-item><term>TMS</term><def><p id="Par25">Transcranial Magnetic Stimulation</p></def></def-item><def-item><term>tDCS</term><def><p id="Par26">Transcranial Direct Current Stimulation</p></def></def-item><def-item><term>VEGF</term><def><p id="Par27">Vascular Endothelial Growth Factor</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>RM &#8211; Conceptualization, Methodology, Writing &#8211;Original Draft, Project Administration, EO &#8211; Data Curation, Investigation, Formal Analysis, IMU &#8211; Software, Validation, Visualization, AVB &#8211; Writing &#8211; Review &amp; Editing, Supervision, PMA &#8211; Resources, Supervision, Methodological Oversight, SDT &#8211; Literature Review, Data, Graphical Abstract Preparation, Manuscript Formatting.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par55">This manuscript is a narrative review and did not involve the collection or analysis of primary data from human participants or animals. Therefore, ethical approval was not required.</p></notes><notes id="FPar1"><title>Consent for publication</title><p id="Par56">Not applicable. This manuscript does not contain any individual person&#8217;s data in any form.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par57">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdelhak</surname><given-names>A</given-names></name><name name-style="western"><surname>Foschi</surname><given-names>M</given-names></name><name name-style="western"><surname>Abu-Rumeileh</surname><given-names>S</given-names></name><name name-style="western"><surname>Yue</surname><given-names>JK</given-names></name><name name-style="western"><surname>D&#8217;Anna</surname><given-names>L</given-names></name><name name-style="western"><surname>Huss</surname><given-names>A</given-names></name><name name-style="western"><surname>Oeckl</surname><given-names>P</given-names></name><name name-style="western"><surname>Ludolph</surname><given-names>AC</given-names></name><name name-style="western"><surname>Kuhle</surname><given-names>J</given-names></name><name name-style="western"><surname>Petzold</surname><given-names>A</given-names></name><name name-style="western"><surname>Manley</surname><given-names>GT</given-names></name><name name-style="western"><surname>Green</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Otto</surname><given-names>M</given-names></name><name name-style="western"><surname>Tumani</surname><given-names>H</given-names></name></person-group><article-title>Blood GFAP as an emerging biomarker in brain and spinal cord disorders</article-title><source>Nat Reviews Neurol 2022</source><year>2022</year><volume>18:3</volume><issue>3</issue><fpage>158</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1038/s41582-021-00616-3</pub-id><pub-id pub-id-type="pmid">35115728</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Abdelhak A, Foschi M, Abu-Rumeileh S, Yue JK, D&#8217;Anna L, Huss A, Oeckl P, Ludolph AC, Kuhle J, Petzold A, Manley GT, Green AJ, Otto M, Tumani H. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Reviews Neurol 2022. 2022;18:3(3):158&#8211;72. 10.1038/s41582-021-00616-3. <italic toggle="yes">18</italic>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-021-00616-3</pub-id><pub-id pub-id-type="pmid">35115728</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aboumerhi</surname><given-names>H</given-names></name><name name-style="western"><surname>Vucetic</surname><given-names>H</given-names></name><name name-style="western"><surname>Gruenzel</surname><given-names>A</given-names></name><name name-style="western"><surname>Moftakhar</surname><given-names>B</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>M</given-names></name><name name-style="western"><surname>Rao</surname><given-names>SK</given-names></name><name name-style="western"><surname>Staudt</surname><given-names>MD</given-names></name></person-group><article-title>The treatment of chemotherapy-induced peripheral neuropathy: a review of current management options and a potential role for scrambler therapy</article-title><source>Front Pain Res</source><year>2025</year><volume>6</volume><fpage>1607102</fpage><pub-id pub-id-type="doi">10.3389/FPAIN.2025.1607102/BIBTEX</pub-id><pub-id pub-id-type="pmcid">PMC12277255</pub-id><pub-id pub-id-type="pmid">40692756</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Aboumerhi H, Vucetic H, Gruenzel A, Moftakhar B, Gupta M, Rao SK, Staudt MD. The treatment of chemotherapy-induced peripheral neuropathy: a review of current management options and a potential role for scrambler therapy. Front Pain Res. 2025;6:1607102. 10.3389/FPAIN.2025.1607102/BIBTEX.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpain.2025.1607102</pub-id><pub-id pub-id-type="pmcid">PMC12277255</pub-id><pub-id pub-id-type="pmid">40692756</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3</label><mixed-citation publication-type="other">Abu Mhanna HY, Omar AF, Radzi YM, Oglat AA, Akhdar HF, Ewaidat A, Almahmoud H, Bani Yaseen A, Badarneh ABA, Alhamad L, O., Alhamad L. Systematic review of functional magnetic resonance imaging (fMRI) applications in the preoperative planning and treatment assessment of brain tumors. Heliyon. 2025;11(3). 10.1016/j.heliyon.2025.e42464.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2025.e42464</pub-id><pub-id pub-id-type="pmcid">PMC11850128</pub-id><pub-id pub-id-type="pmid">40007791</pub-id></mixed-citation></ref><ref id="CR4"><label>4</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amani</surname><given-names>O</given-names></name><name name-style="western"><surname>Mazaheri</surname><given-names>MA</given-names></name><name name-style="western"><surname>Moghani</surname><given-names>MM</given-names></name><name name-style="western"><surname>Zarani</surname><given-names>F</given-names></name><name name-style="western"><surname>Choolabi</surname><given-names>RH</given-names></name></person-group><article-title>Chemotherapy-induced cognitive impairment in breast cancer survivors: A systematic review of studies from 2000 to 2021</article-title><source>CancerRep</source><year>2024</year><volume>7</volume><issue>2</issue><fpage>e1989</fpage><pub-id pub-id-type="doi">10.1002/CNR2.1989;WGROUP:STRING:PUBLICATION</pub-id><pub-id pub-id-type="pmcid">PMC10864736</pub-id><pub-id pub-id-type="pmid">38351543</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Amani O, Mazaheri MA, Moghani MM, Zarani F, Choolabi RH. Chemotherapy-induced cognitive impairment in breast cancer survivors: A systematic review of studies from 2000 to 2021. Cancer Rep. 2024;7(2):e1989. 10.1002/CNR2.1989;WGROUP:STRING:PUBLICATION.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cnr2.1989</pub-id><pub-id pub-id-type="pmcid">PMC10864736</pub-id><pub-id pub-id-type="pmid">38351543</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amin</surname><given-names>ARMR</given-names></name><name name-style="western"><surname>Alqahtani</surname><given-names>S</given-names></name><name name-style="western"><surname>Bitar</surname><given-names>SD</given-names></name><name name-style="western"><surname>Mireles</surname><given-names>ME</given-names></name><name name-style="western"><surname>Corrales-Medina</surname><given-names>FF</given-names></name><name name-style="western"><surname>Herzog</surname><given-names>CE</given-names></name><name name-style="western"><surname>Slopis</surname><given-names>J</given-names></name><name name-style="western"><surname>Daw</surname><given-names>NC</given-names></name></person-group><article-title>Ifosfamide-Induced encephalopathy in children and young adults: the MD Anderson cancer center experience</article-title><source>Cancers 2025</source><year>2025</year><volume>17</volume><issue>13</issue><fpage>2192</fpage><pub-id pub-id-type="doi">10.3390/CANCERS17132192</pub-id><pub-id pub-id-type="pmcid">PMC12249253</pub-id><pub-id pub-id-type="pmid">40647490</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Amin ARMR, Alqahtani S, Bitar SD, Mireles ME, Corrales-Medina FF, Herzog CE, Slopis J, Daw NC. Ifosfamide-Induced encephalopathy in children and young adults: the MD Anderson cancer center experience. Cancers 2025. 2025;17(13):2192. 10.3390/CANCERS17132192. <italic toggle="yes">17</italic>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers17132192</pub-id><pub-id pub-id-type="pmcid">PMC12249253</pub-id><pub-id pub-id-type="pmid">40647490</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bansal</surname><given-names>R</given-names></name><name name-style="western"><surname>Bhojwani</surname><given-names>D</given-names></name><name name-style="western"><surname>Sun</surname><given-names>BF</given-names></name><name name-style="western"><surname>Sawardekar</surname><given-names>S</given-names></name><name name-style="western"><surname>Wayne</surname><given-names>AS</given-names></name><name name-style="western"><surname>Ouassil</surname><given-names>H</given-names></name><name name-style="western"><surname>Gupte</surname><given-names>C</given-names></name><name name-style="western"><surname>Marcelino</surname><given-names>C</given-names></name><name name-style="western"><surname>Anaya</surname><given-names>G</given-names></name><name name-style="western"><surname>Luna</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>BS</given-names></name></person-group><article-title>Progression of brain injuries associated with methotrexate chemotherapy in childhood acute lymphoblastic leukemia</article-title><source>Pediatr Res</source><year>2024</year><volume>97</volume><issue>1</issue><fpage>348</fpage><pub-id pub-id-type="doi">10.1038/S41390-024-03351-9</pub-id><pub-id pub-id-type="pmid">38951657</pub-id><pub-id pub-id-type="pmcid">PMC11798858</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Bansal R, Bhojwani D, Sun BF, Sawardekar S, Wayne AS, Ouassil H, Gupte C, Marcelino C, Anaya G, Luna MJ, N., Peterson BS. Progression of brain injuries associated with methotrexate chemotherapy in childhood acute lymphoblastic leukemia. Pediatr Res. 2024;97(1):348. 10.1038/S41390-024-03351-9.<pub-id pub-id-type="pmid">38951657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41390-024-03351-9</pub-id><pub-id pub-id-type="pmcid">PMC11798858</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhol</surname><given-names>NK</given-names></name><name name-style="western"><surname>Bhanjadeo</surname><given-names>MM</given-names></name><name name-style="western"><surname>Singh</surname><given-names>AK</given-names></name><name name-style="western"><surname>Dash</surname><given-names>UC</given-names></name><name name-style="western"><surname>Ojha</surname><given-names>RR</given-names></name><name name-style="western"><surname>Majhi</surname><given-names>S</given-names></name><name name-style="western"><surname>Duttaroy</surname><given-names>AK</given-names></name><name name-style="western"><surname>Jena</surname><given-names>AB</given-names></name></person-group><article-title>The interplay between cytokines, inflammation, and antioxidants: mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine compounds</article-title><source>Biomed Pharmacother</source><year>2024</year><volume>178</volume><fpage>117177</fpage><pub-id pub-id-type="doi">10.1016/J.BIOPHA.2024.117177</pub-id><pub-id pub-id-type="pmid">39053423</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Bhol NK, Bhanjadeo MM, Singh AK, Dash UC, Ojha RR, Majhi S, Duttaroy AK, Jena AB. The interplay between cytokines, inflammation, and antioxidants: mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine compounds. Biomed Pharmacother. 2024;178:117177. 10.1016/J.BIOPHA.2024.117177.<pub-id pub-id-type="pmid">39053423</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2024.117177</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buccilli</surname><given-names>B</given-names></name><name name-style="western"><surname>Alan</surname><given-names>A</given-names></name><name name-style="western"><surname>Aljeradat</surname><given-names>B</given-names></name><name name-style="western"><surname>Shahzad</surname><given-names>A</given-names></name><name name-style="western"><surname>Almealawy</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chisvo</surname><given-names>NS</given-names></name><name name-style="western"><surname>Ennabe</surname><given-names>M</given-names></name><name name-style="western"><surname>Weinand</surname><given-names>M</given-names></name></person-group><article-title>Neuroprotection strategies in traumatic brain injury: studying the effectiveness of different clinical approaches</article-title><source>Surg Neurol Int</source><year>2024</year><volume>15</volume><fpage>29</fpage><pub-id pub-id-type="doi">10.25259/SNI_773_2023</pub-id><pub-id pub-id-type="pmid">38344087</pub-id><pub-id pub-id-type="pmcid">PMC10858774</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Buccilli B, Alan A, Aljeradat B, Shahzad A, Almealawy Y, Chisvo NS, Ennabe M, Weinand M. Neuroprotection strategies in traumatic brain injury: studying the effectiveness of different clinical approaches. Surg Neurol Int. 2024;15:29. 10.25259/SNI_773_2023.<pub-id pub-id-type="pmid">38344087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.25259/SNI_773_2023</pub-id><pub-id pub-id-type="pmcid">PMC10858774</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cazalla</surname><given-names>E</given-names></name><name name-style="western"><surname>Cuadrado</surname><given-names>A</given-names></name><name name-style="western"><surname>Garc&#237;a-Yag&#252;e</surname><given-names>&#193;J</given-names></name></person-group><article-title>Role of the transcription factor NRF2 in maintaining the integrity of the Blood-Brain barrier</article-title><source>Fluids Barriers CNS 2024</source><year>2024</year><volume>21:1</volume><issue>1</issue><fpage>1</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1186/S12987-024-00599-5</pub-id><pub-id pub-id-type="pmcid">PMC11580557</pub-id><pub-id pub-id-type="pmid">39574123</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Cazalla E, Cuadrado A, Garc&#237;a-Yag&#252;e &#193;J. Role of the transcription factor NRF2 in maintaining the integrity of the Blood-Brain barrier. Fluids Barriers CNS 2024. 2024;21:1(1):1&#8211;29.10.1186/S12987-024-00599-5. <italic toggle="yes">21</italic>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12987-024-00599-5</pub-id><pub-id pub-id-type="pmcid">PMC11580557</pub-id><pub-id pub-id-type="pmid">39574123</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C</given-names></name><name name-style="western"><surname>Ran</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Shen</surname><given-names>C</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Song</surname><given-names>L</given-names></name><name name-style="western"><surname>Peng</surname><given-names>C</given-names></name></person-group><article-title>Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: mechanisms, pharmacokinetics and strategies</article-title><source>Front Pharmacol</source><year>2023</year><volume>14</volume><fpage>1231401</fpage><pub-id pub-id-type="doi">10.3389/FPHAR.2023.1231401/FULL</pub-id><pub-id pub-id-type="pmid">37593174</pub-id><pub-id pub-id-type="pmcid">PMC10427877</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Cheng F, Zhang R, Sun C, Ran Q, Zhang C, Shen C, Yao Z, Wang M, Song L, Peng C. Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: mechanisms, pharmacokinetics and strategies. Front Pharmacol. 2023a;14:1231401. 10.3389/FPHAR.2023.1231401/FULL.<pub-id pub-id-type="pmid">37593174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2023.1231401</pub-id><pub-id pub-id-type="pmcid">PMC10427877</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C</given-names></name><name name-style="western"><surname>Ran</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Shen</surname><given-names>C</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Song</surname><given-names>L</given-names></name><name name-style="western"><surname>Peng</surname><given-names>C</given-names></name></person-group><article-title>Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: mechanisms, pharmacokinetics and strategies</article-title><source>Front Pharmacol</source><year>2023</year><volume>14</volume><fpage>1231401</fpage><pub-id pub-id-type="doi">10.3389/FPHAR.2023.1231401/XML</pub-id><pub-id pub-id-type="pmid">37593174</pub-id><pub-id pub-id-type="pmcid">PMC10427877</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Cheng F, Zhang R, Sun C, Ran Q, Zhang C, Shen C, Yao Z, Wang M, Song L, Peng C. Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: mechanisms, pharmacokinetics and strategies. Front Pharmacol. 2023b;14:1231401. 10.3389/FPHAR.2023.1231401/XML.<pub-id pub-id-type="pmid">37593174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2023.1231401</pub-id><pub-id pub-id-type="pmcid">PMC10427877</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiu</surname><given-names>D</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>J</given-names></name><name name-style="western"><surname>Gonzalez Castro</surname><given-names>LN</given-names></name></person-group><article-title>Diagnosis and treatment of paraneoplastic neurologic syndromes</article-title><source>Antibodies</source><year>2023</year><volume>12</volume><issue>3</issue><fpage>50</fpage><pub-id pub-id-type="doi">10.3390/ANTIB12030050</pub-id><pub-id pub-id-type="pmid">37606434</pub-id><pub-id pub-id-type="pmcid">PMC10443237</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Chiu D, Rhee J, Gonzalez Castro LN. Diagnosis and treatment of paraneoplastic neurologic syndromes. Antibodies. 2023;12(3):50. 10.3390/ANTIB12030050.<pub-id pub-id-type="pmid">37606434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antib12030050</pub-id><pub-id pub-id-type="pmcid">PMC10443237</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13</label><mixed-citation publication-type="other">Chung N-C, Chang A, Gillis R, Sloan E, Walker AK. (2021). Paclitaxel chemotherapy induces Long-Term memory impairment and neuroinammation in a mouse model of breast cancer survivorship. 10.21203/rs.3.rs-783452/v1</mixed-citation></ref><ref id="CR14"><label>14</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cicatiello</surname><given-names>AG</given-names></name><name name-style="western"><surname>Musone</surname><given-names>M</given-names></name><name name-style="western"><surname>Imperatore</surname><given-names>S</given-names></name><name name-style="western"><surname>Giulioni</surname><given-names>C</given-names></name><name name-style="western"><surname>La Rocca</surname><given-names>R</given-names></name><name name-style="western"><surname>Cafarelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Del Giudice</surname><given-names>F</given-names></name><name name-style="western"><surname>Dentice</surname><given-names>M</given-names></name><name name-style="western"><surname>Crocetto</surname><given-names>F</given-names></name></person-group><article-title>Circulating MiRNAs in genitourinary cancer: pioneering advances in early detection and diagnosis</article-title><source>J Liquid Biopsy</source><year>2025</year><volume>8</volume><fpage>100296</fpage><pub-id pub-id-type="doi">10.1016/J.JLB.2025.100296</pub-id><pub-id pub-id-type="pmcid">PMC12088820</pub-id><pub-id pub-id-type="pmid">40391154</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Cicatiello AG, Musone M, Imperatore S, Giulioni C, La Rocca R, Cafarelli A, Del Giudice F, Dentice M, Crocetto F. Circulating MiRNAs in genitourinary cancer: pioneering advances in early detection and diagnosis. J Liquid Biopsy. 2025;8:100296. 10.1016/J.JLB.2025.100296.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jlb.2025.100296</pub-id><pub-id pub-id-type="pmcid">PMC12088820</pub-id><pub-id pub-id-type="pmid">40391154</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coradi</surname><given-names>C</given-names></name><name name-style="western"><surname>Vacario</surname><given-names>BGL</given-names></name><name name-style="western"><surname>Sotomayor</surname><given-names>MR</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>VP</given-names></name><name name-style="western"><surname>Bellandi</surname><given-names>GB</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>LCF</given-names></name><name name-style="western"><surname>de Almeida</surname><given-names>CF</given-names></name><name name-style="western"><surname>Panis</surname><given-names>C</given-names></name></person-group><article-title>Paraneoplastic neurologic syndromes in breast cancer: immunological mechanisms and therapeutic insights</article-title><source>Clin Immunol Commun</source><year>2025</year><volume>8</volume><fpage>26</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/J.CLICOM.2025.06.003</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Coradi C, Vacario BGL, Sotomayor MR, da Silva VP, Bellandi GB, da Silva LCF, de Almeida CF, Panis C. Paraneoplastic neurologic syndromes in breast cancer: immunological mechanisms and therapeutic insights. Clin Immunol Commun. 2025;8:26&#8211;37. 10.1016/J.CLICOM.2025.06.003.</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dantzer</surname><given-names>R</given-names></name></person-group><article-title>Neuroimmune interactions: from the brain to the immune system and vice versa</article-title><source>Physiol Rev</source><year>2018</year><volume>98</volume><issue>1</issue><fpage>477</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1152/physrev.00039.2016</pub-id><pub-id pub-id-type="pmid">29351513</pub-id><pub-id pub-id-type="pmcid">PMC5866360</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Dantzer R. Neuroimmune interactions: from the brain to the immune system and vice versa. Physiol Rev. 2018;98(1):477&#8211;504. 10.1152/physrev.00039.2016.<pub-id pub-id-type="pmid">29351513</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.00039.2016</pub-id><pub-id pub-id-type="pmcid">PMC5866360</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17</label><mixed-citation publication-type="other">D&#233;chelotte B, Mu&#241;iz-Castrillo S, Joubert B, Vogrig A, Picard G, Rogemond V, Pinto AL, Lombard C, Desestret V, Fabien N, Honnorat J. Diagnostic yield of commercial Immunodots to diagnose paraneoplastic neurologic syndromes. Neurology: Neuroimmunol NeuroInflammation. 2020;7(3). 10.1212/NXI.0000000000000701.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/NXI.0000000000000701</pub-id><pub-id pub-id-type="pmcid">PMC7136063</pub-id><pub-id pub-id-type="pmid">32170044</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Demos-Davies K, Lawrence J, Seelig D. (2024). <italic toggle="yes">Cancer related cognitive impairment: a downside of cancer treatment</italic>. 10.3389/fonc.2024.1387251<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2024.1387251</pub-id><pub-id pub-id-type="pmcid">PMC11074410</pub-id><pub-id pub-id-type="pmid">38715789</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Demos-Davies</surname><given-names>K</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>J</given-names></name><name name-style="western"><surname>Seelig</surname><given-names>D</given-names></name></person-group><article-title>Cancer related cognitive impairment: a downside of cancer treatment</article-title><source>Front Oncol</source><year>2024</year><volume>14</volume><fpage>1387251</fpage><pub-id pub-id-type="doi">10.3389/FONC.2024.1387251</pub-id><pub-id pub-id-type="pmid">38715789</pub-id><pub-id pub-id-type="pmcid">PMC11074410</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Demos-Davies K, Lawrence J, Seelig D. Cancer related cognitive impairment: a downside of cancer treatment. Front Oncol. 2024a;14:1387251. 10.3389/FONC.2024.1387251.<pub-id pub-id-type="pmid">38715789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2024.1387251</pub-id><pub-id pub-id-type="pmcid">PMC11074410</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devine</surname><given-names>MF</given-names></name><name name-style="western"><surname>Kothapalli</surname><given-names>N</given-names></name><name name-style="western"><surname>Elkhooly</surname><given-names>M</given-names></name><name name-style="western"><surname>Dubey</surname><given-names>D</given-names></name></person-group><article-title>Paraneoplastic neurological syndromes: clinical presentations and management</article-title><source>Ther Adv Neurol Disord</source><year>2021</year><volume>14</volume><fpage>1756286420985323</fpage><pub-id pub-id-type="doi">10.1177/1756286420985323</pub-id><pub-id pub-id-type="pmid">33796141</pub-id><pub-id pub-id-type="pmcid">PMC7970694</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Devine MF, Kothapalli N, Elkhooly M, Dubey D. Paraneoplastic neurological syndromes: clinical presentations and management. Ther Adv Neurol Disord. 2021;14:1756286420985323. 10.1177/1756286420985323.<pub-id pub-id-type="pmid">33796141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1756286420985323</pub-id><pub-id pub-id-type="pmcid">PMC7970694</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21</label><mixed-citation publication-type="other">Dhas N, Kudarha R, Kulkarni S, Soman S, Navti PD, Kulkarni J, Roy AA, Colaco V, Raychaudhuri R, Gupta A, Pardeshi C, Bari D, Tiwari R, Patel J, Moorkoth S, Mutalik S. Nanoengineered Platform-Based Microenvironment-Triggered immunotherapy in cancer treatment. Front Bioscience - Landmark. 2024;29(10). 10.31083/J.FBL2910349/2768-6698-29-10-349/FIG1.JPG.<pub-id pub-id-type="doi" assigning-authority="pmc">10.31083/j.fbl2910349</pub-id><pub-id pub-id-type="pmid">39473401</pub-id></mixed-citation></ref><ref id="CR22"><label>22</label><mixed-citation publication-type="other">Dufresne SS, Jardel P, Brassard M, Bilodeau P, Grand&#8217;Maison E, De, Dufresne SS, Jardel P, Brassard M, Bilodeau P, Grand&#8217;Maison E, De. (2025). Integrated Approaches to Managing Cancer Treatment-Induced Peripheral Neuropathies: Risk Factors, Interventions, and Clinical Pathways. <italic toggle="yes">Peripheral Neuropathy - Causes, Symptoms, and Treatment Options [Working Title]</italic>. 10.5772/INTECHOPEN.1011121</mixed-citation></ref><ref id="CR23"><label>23</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esperan&#231;a-Martins</surname><given-names>M</given-names></name><name name-style="western"><surname>Roque</surname><given-names>D</given-names></name><name name-style="western"><surname>Barroso</surname><given-names>T</given-names></name><name name-style="western"><surname>Abrunhosa-Branquinho</surname><given-names>A</given-names></name><name name-style="western"><surname>Belo</surname><given-names>D</given-names></name><name name-style="western"><surname>Simas</surname><given-names>N</given-names></name><name name-style="western"><surname>Costa</surname><given-names>L</given-names></name></person-group><article-title>Multidisciplinary approach to spinal metastases and metastatic spinal cord Compression&#8212;A new integrative flowchart for patient management</article-title><source>Cancers 2023</source><year>2023</year><volume>15</volume><issue>6</issue><fpage>1796</fpage><pub-id pub-id-type="doi">10.3390/CANCERS15061796</pub-id><pub-id pub-id-type="pmcid">PMC10046378</pub-id><pub-id pub-id-type="pmid">36980681</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Esperan&#231;a-Martins M, Roque D, Barroso T, Abrunhosa-Branquinho A, Belo D, Simas N, Costa L. Multidisciplinary approach to spinal metastases and metastatic spinal cord Compression&#8212;A new integrative flowchart for patient management. Cancers 2023. 2023;15(6):1796. 10.3390/CANCERS15061796. <italic toggle="yes">15</italic>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers15061796</pub-id><pub-id pub-id-type="pmcid">PMC10046378</pub-id><pub-id pub-id-type="pmid">36980681</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farina</surname><given-names>A</given-names></name><name name-style="western"><surname>Birzu</surname><given-names>C</given-names></name><name name-style="western"><surname>Elsensohn</surname><given-names>MH</given-names></name><name name-style="western"><surname>Picca</surname><given-names>A</given-names></name><name name-style="western"><surname>Muniz-Castrillo</surname><given-names>S</given-names></name><name name-style="western"><surname>Vogrig</surname><given-names>A</given-names></name><name name-style="western"><surname>Villagran-Garcia</surname><given-names>M</given-names></name><name name-style="western"><surname>Ciano-Petersen</surname><given-names>NL</given-names></name><name name-style="western"><surname>Massacesi</surname><given-names>L</given-names></name><name name-style="western"><surname>Hervier</surname><given-names>B</given-names></name><name name-style="western"><surname>Guegan</surname><given-names>S</given-names></name><name name-style="western"><surname>Kramkimel</surname><given-names>N</given-names></name><name name-style="western"><surname>Vano</surname><given-names>Y</given-names></name><name name-style="western"><surname>Salem</surname><given-names>JE</given-names></name><name name-style="western"><surname>Allenbach</surname><given-names>Y</given-names></name><name name-style="western"><surname>Maisonobe</surname><given-names>T</given-names></name><name name-style="western"><surname>Assaad</surname><given-names>S</given-names></name><name name-style="western"><surname>Maureille</surname><given-names>A</given-names></name><name name-style="western"><surname>Devic</surname><given-names>P</given-names></name><name name-style="western"><surname>Joubert</surname><given-names>B</given-names></name></person-group><article-title>Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity</article-title><source>Brain Commun</source><year>2023</year><volume>5</volume><issue>3</issue><fpage>fcad169</fpage><pub-id pub-id-type="doi">10.1093/BRAINCOMMS/FCAD169</pub-id><pub-id pub-id-type="pmid">37389303</pub-id><pub-id pub-id-type="pmcid">PMC10306160</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Farina A, Birzu C, Elsensohn MH, Picca A, Muniz-Castrillo S, Vogrig A, Villagran-Garcia M, Ciano-Petersen NL, Massacesi L, Hervier B, Guegan S, Kramkimel N, Vano Y, Salem JE, Allenbach Y, Maisonobe T, Assaad S, Maureille A, Devic P, Joubert B. Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. Brain Commun. 2023;5(3):fcad169. 10.1093/BRAINCOMMS/FCAD169.<pub-id pub-id-type="pmid">37389303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcad169</pub-id><pub-id pub-id-type="pmcid">PMC10306160</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fayette</surname><given-names>D</given-names></name><name name-style="western"><surname>Jur&#237;&#269;kov&#225;</surname><given-names>V</given-names></name><name name-style="western"><surname>Koz&#225;k</surname><given-names>T</given-names></name><name name-style="western"><surname>Mocikov&#225;</surname><given-names>H</given-names></name><name name-style="western"><surname>Gaherov&#225;</surname><given-names>L</given-names></name><name name-style="western"><surname>Fajnerov&#225;</surname><given-names>I</given-names></name><name name-style="western"><surname>Hor&#225;&#269;ek</surname><given-names>J</given-names></name></person-group><article-title>Cognitive impairment associated with hodgkin&#8217;s lymphoma and chemotherapy</article-title><source>Neurosci Lett</source><year>2023</year><volume>797</volume><fpage>137082</fpage><pub-id pub-id-type="doi">10.1016/J.NEULET.2023.137082</pub-id><pub-id pub-id-type="pmid">36693557</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Fayette D, Jur&#237;&#269;kov&#225; V, Koz&#225;k T, Mocikov&#225; H, Gaherov&#225; L, Fajnerov&#225; I, Hor&#225;&#269;ek J. Cognitive impairment associated with hodgkin&#8217;s lymphoma and chemotherapy. Neurosci Lett. 2023;797:137082. 10.1016/J.NEULET.2023.137082.<pub-id pub-id-type="pmid">36693557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2023.137082</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26</label><mixed-citation publication-type="other">Gangireddy M, Patel P, Nookala V. (2024). Ifosfamide. <italic toggle="yes">XPharm: The Comprehensive Pharmacology Reference</italic>, 1&#8211;4. 10.1016/B978-008055232-3.61914-2</mixed-citation></ref><ref id="CR27"><label>27</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaynor</surname><given-names>AM</given-names></name><name name-style="western"><surname>Pergolizzi</surname><given-names>D</given-names></name><name name-style="western"><surname>Alici</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>E</given-names></name><name name-style="western"><surname>McNeal</surname><given-names>K</given-names></name><name name-style="western"><surname>Ahles</surname><given-names>TA</given-names></name><name name-style="western"><surname>Root</surname><given-names>JC</given-names></name></person-group><article-title>Impact of transcranial direct current stimulation on sustained attention in breast cancer survivors: evidence for feasibility, tolerability, and initial efficacy</article-title><source>Brain Stimul</source><year>2020</year><volume>13</volume><issue>4</issue><fpage>1108</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.brs.2020.04.013</pub-id><pub-id pub-id-type="pmid">32353419</pub-id><pub-id pub-id-type="pmcid">PMC7446233</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Gaynor AM, Pergolizzi D, Alici Y, Ryan E, McNeal K, Ahles TA, Root JC. Impact of transcranial direct current stimulation on sustained attention in breast cancer survivors: evidence for feasibility, tolerability, and initial efficacy. Brain Stimul. 2020;13(4):1108&#8211;16. 10.1016/j.brs.2020.04.013.<pub-id pub-id-type="pmid">32353419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brs.2020.04.013</pub-id><pub-id pub-id-type="pmcid">PMC7446233</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghadimi</surname><given-names>K</given-names></name><name name-style="western"><surname>Abbas</surname><given-names>I</given-names></name><name name-style="western"><surname>Karandish</surname><given-names>A</given-names></name><name name-style="western"><surname>Crisman</surname><given-names>C</given-names></name><name name-style="western"><surname>Eskandar</surname><given-names>EN</given-names></name><name name-style="western"><surname>Kobets</surname><given-names>AJ</given-names></name></person-group><article-title>Cognitive decline in glioblastoma (GB) patients with different treatment modalities and insights on untreated cases</article-title><source>Curr Oncol 2025</source><year>2025</year><volume>32</volume><issue>3</issue><fpage>152</fpage><pub-id pub-id-type="doi">10.3390/CURRONCOL32030152</pub-id><pub-id pub-id-type="pmcid">PMC11940939</pub-id><pub-id pub-id-type="pmid">40136356</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Ghadimi K, Abbas I, Karandish A, Crisman C, Eskandar EN, Kobets AJ. Cognitive decline in glioblastoma (GB) patients with different treatment modalities and insights on untreated cases. Curr Oncol 2025. 2025;32(3):152. 10.3390/CURRONCOL32030152. <italic toggle="yes">32</italic>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/curroncol32030152</pub-id><pub-id pub-id-type="pmcid">PMC11940939</pub-id><pub-id pub-id-type="pmid">40136356</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilligan</surname><given-names>M</given-names></name><name name-style="western"><surname>McGuigan</surname><given-names>C</given-names></name><name name-style="western"><surname>McKeon</surname><given-names>A</given-names></name></person-group><article-title>Paraneoplastic neurologic disorders</article-title><source>Curr Neurol Neurosci Rep</source><year>2023</year><volume>23</volume><issue>3</issue><fpage>67</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1007/S11910-023-01250-W/FIGURES/1</pub-id><pub-id pub-id-type="pmid">36781586</pub-id><pub-id pub-id-type="pmcid">PMC10011323</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Gilligan M, McGuigan C, McKeon A. Paraneoplastic neurologic disorders. Curr Neurol Neurosci Rep. 2023;23(3):67&#8211;82. 10.1007/S11910-023-01250-W/FIGURES/1.<pub-id pub-id-type="pmid">36781586</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11910-023-01250-w</pub-id><pub-id pub-id-type="pmcid">PMC10011323</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golden</surname><given-names>EP</given-names></name><name name-style="western"><surname>Vernino</surname><given-names>S</given-names></name></person-group><article-title>Paraneoplastic autonomic neuropathies and GI dysmotility</article-title><source>Handb Clin Neurol</source><year>2024</year><volume>200</volume><fpage>275</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-823912-4.00005-0</pub-id><pub-id pub-id-type="pmid">38494282</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Golden EP, Vernino S. Paraneoplastic autonomic neuropathies and GI dysmotility. Handb Clin Neurol. 2024;200:275&#8211;82. 10.1016/B978-0-12-823912-4.00005-0.<pub-id pub-id-type="pmid">38494282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-12-823912-4.00005-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>J</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wei</surname><given-names>G</given-names></name><name name-style="western"><surname>Huo</surname><given-names>J</given-names></name></person-group><article-title>Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis</article-title><source>Support CareCancer</source><year>2021</year><volume>29</volume><issue>12</issue><fpage>7461</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/S00520-021-06321-7</pub-id><pub-id pub-id-type="pmcid">PMC8550712</pub-id><pub-id pub-id-type="pmid">34085148</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Gu J, Lu H, Chen C, Gu Z, Hu M, Liu L, Yu J, Wei G, Huo J. Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis. Support Care Cancer. 2021;29(12):7461&#8211;9. 10.1007/S00520-021-06321-7.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00520-021-06321-7</pub-id><pub-id pub-id-type="pmcid">PMC8550712</pub-id><pub-id pub-id-type="pmid">34085148</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32</label><mixed-citation publication-type="other">Gu Q, Wang L, King TZ, Chen H, Zhang L, Ni J, Mao H. Seeing through brain fog: neuroimaging assessment and imaging biomarkers for cancer-related cognitive impairments. Cancer Imaging. 2024;24(1). 10.1186/S40644-024-00797-2.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40644-024-00797-2</pub-id><pub-id pub-id-type="pmcid">PMC11572057</pub-id><pub-id pub-id-type="pmid">39558401</pub-id></mixed-citation></ref><ref id="CR33"><label>33</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gualtieri</surname><given-names>P</given-names></name><name name-style="western"><surname>Frank</surname><given-names>G</given-names></name><name name-style="western"><surname>Cianci</surname><given-names>R</given-names></name><name name-style="western"><surname>Ciancarella</surname><given-names>L</given-names></name><name name-style="western"><surname>Romano</surname><given-names>L</given-names></name><name name-style="western"><surname>Ortoman</surname><given-names>M</given-names></name><name name-style="western"><surname>Bigioni</surname><given-names>G</given-names></name><name name-style="western"><surname>Nicoletti</surname><given-names>F</given-names></name><name name-style="western"><surname>Falco</surname><given-names>MI</given-names></name><name name-style="western"><surname>La Placa</surname><given-names>G</given-names></name><name name-style="western"><surname>Di Renzo</surname><given-names>L</given-names></name></person-group><article-title>Exploring the efficacy and safety of nutritional supplements in alzheimer&#8217;s disease</article-title><source>Nutrients</source><year>2025</year><volume>17</volume><issue>5</issue><fpage>922</fpage><pub-id pub-id-type="doi">10.3390/NU17050922</pub-id><pub-id pub-id-type="pmid">40077790</pub-id><pub-id pub-id-type="pmcid">PMC11901643</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Gualtieri P, Frank G, Cianci R, Ciancarella L, Romano L, Ortoman M, Bigioni G, Nicoletti F, Falco MI, La Placa G, Di Renzo L. Exploring the efficacy and safety of nutritional supplements in alzheimer&#8217;s disease. Nutrients. 2025;17(5):922. 10.3390/NU17050922.<pub-id pub-id-type="pmid">40077790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu17050922</pub-id><pub-id pub-id-type="pmcid">PMC11901643</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janigro</surname><given-names>D</given-names></name><name name-style="western"><surname>Mondello</surname><given-names>S</given-names></name><name name-style="western"><surname>Posti</surname><given-names>JP</given-names></name><name name-style="western"><surname>Unden</surname><given-names>J</given-names></name></person-group><article-title>GFAP and S100B: what you always wanted to know and never dared to ask</article-title><source>Front Neurol</source><year>2022</year><volume>13</volume><fpage>835597</fpage><pub-id pub-id-type="doi">10.3389/FNEUR.2022.835597</pub-id><pub-id pub-id-type="pmid">35386417</pub-id><pub-id pub-id-type="pmcid">PMC8977512</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Janigro D, Mondello S, Posti JP, Unden J. GFAP and S100B: what you always wanted to know and never dared to ask. Front Neurol. 2022;13:835597. 10.3389/FNEUR.2022.835597.<pub-id pub-id-type="pmid">35386417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2022.835597</pub-id><pub-id pub-id-type="pmcid">PMC8977512</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jean-Pierre</surname><given-names>P</given-names></name></person-group><article-title>Integrating functional near-infrared spectroscopy in the characterization, assessment, and monitoring of cancer and treatment-related neurocognitive dysfunction</article-title><source>NeuroImage</source><year>2014</year><volume>85</volume><fpage>408</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2013.06.075</pub-id><pub-id pub-id-type="pmid">23831530</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Jean-Pierre P. Integrating functional near-infrared spectroscopy in the characterization, assessment, and monitoring of cancer and treatment-related neurocognitive dysfunction. NeuroImage. 2014;85:408&#8211;14. 10.1016/j.neuroimage.2013.06.075.<pub-id pub-id-type="pmid">23831530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2013.06.075</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Justiz-Vaillant</surname><given-names>A</given-names></name><name name-style="western"><surname>Soodeen</surname><given-names>S</given-names></name><name name-style="western"><surname>Asin-Milan</surname><given-names>O</given-names></name><name name-style="western"><surname>Morales-Esquivel</surname><given-names>J</given-names></name><name name-style="western"><surname>Arozarena-Fundora</surname><given-names>R</given-names></name></person-group><article-title>Efficacy of intravenous Immunoglobulins and other immunotherapies in neurological disorders and immunological mechanisms involved</article-title><source>Immuno 2025</source><year>2025</year><volume>5</volume><issue>2</issue><fpage>18</fpage><pub-id pub-id-type="doi">10.3390/IMMUNO5020018</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Justiz-Vaillant A, Soodeen S, Asin-Milan O, Morales-Esquivel J, Arozarena-Fundora R. Efficacy of intravenous Immunoglobulins and other immunotherapies in neurological disorders and immunological mechanisms involved. Immuno 2025. 2025;5(2):18. 10.3390/IMMUNO5020018. <italic toggle="yes">5</italic>.</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37</label><mixed-citation publication-type="other">Kapoor I, Sarvepalli SM, Grewal DS,Hadziahmetovic M. Clinical outcomes of therapeutic interventions for autoimmune retinopathy: A Meta-analysis and systematic review. Ophthalmol Sci. 2025;5(1). 10.1016/j.xops.2024.100622.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xops.2024.100622</pub-id><pub-id pub-id-type="pmcid">PMC11635770</pub-id><pub-id pub-id-type="pmid">39669695</pub-id></mixed-citation></ref><ref id="CR38"><label>38</label><mixed-citation publication-type="other">Karahasanovi&#263; N, Gruber T, D&#246;rl G, Radjenovic S, Kolarova T, Matt E, Beisteiner R. Brain plasticity in fMRI and DTI. Med Radiol. 2022;387&#8211;406. 10.1007/978-3-030-83343-5_11.</mixed-citation></ref><ref id="CR39"><label>39</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>CW</given-names></name><name name-style="western"><surname>Kr&#252;ger</surname><given-names>MT</given-names></name><name name-style="western"><surname>Akram</surname><given-names>H</given-names></name><name name-style="western"><surname>Zrinzo</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>N</given-names></name><name name-style="western"><surname>Rubin</surname><given-names>JS</given-names></name><name name-style="western"><surname>Birchall</surname><given-names>MA</given-names></name><name name-style="western"><surname>Fishman</surname><given-names>JM</given-names></name></person-group><article-title>Neuromodulation for laryngeal dystonia: A systematic review</article-title><source>J Voice</source><year>2025</year><pub-id pub-id-type="doi">10.1016/j.jvoice.2025.03.017</pub-id><pub-id pub-id-type="pmid">40164525</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Lee CW, Kr&#252;ger MT, Akram H, Zrinzo L, Yang W, Hamilton N, Rubin JS, Birchall MA, Fishman JM. Neuromodulation for laryngeal dystonia: A systematic review. J Voice. 2025. 10.1016/j.jvoice.2025.03.017.<pub-id pub-id-type="pmid">40164525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvoice.2025.03.017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40</label><mixed-citation publication-type="other">Leng G, Duan B, Liu J, Li S, Zhao W, Wang S, Hou G, Qu J. The advancements and prospective developments in anti-tumor targeted therapy. Neoplasia (United States). 2024;56. 10.1016/j.neo.2024.101024.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neo.2024.101024</pub-id><pub-id pub-id-type="pmcid">PMC11318541</pub-id><pub-id pub-id-type="pmid">39047659</pub-id></mixed-citation></ref><ref id="CR41"><label>41</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Tong</surname><given-names>F</given-names></name><name name-style="western"><surname>Wu</surname><given-names>B</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X</given-names></name></person-group><article-title>Radiation-Induced brain injury: mechanistic insights and the promise of Gut&#8211;Brain axis therapies</article-title><source>Brain Sci 2024</source><year>2024</year><volume>14</volume><issue>12</issue><fpage>1295</fpage><pub-id pub-id-type="doi">10.3390/BRAINSCI14121295</pub-id><pub-id pub-id-type="pmcid">PMC11674909</pub-id><pub-id pub-id-type="pmid">39766494</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Li M, Tong F, Wu B, Dong X. Radiation-Induced brain injury: mechanistic insights and the promise of Gut&#8211;Brain axis therapies. Brain Sci 2024. 2024;14(12):1295. 10.3390/BRAINSCI14121295. <italic toggle="yes">14</italic>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/brainsci14121295</pub-id><pub-id pub-id-type="pmcid">PMC11674909</pub-id><pub-id pub-id-type="pmid">39766494</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Diagnosis and management of adult central nervous system leukemia</article-title><source>Blood Sci</source><year>2023</year><volume>5</volume><issue>3</issue><fpage>141</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/BS9.0000000000000162/ASSET/159B4FC1-205A-40B6-A9DA-E331B9FBCF3E/ASSETS/GRAPHIC/2543-6368-05-03-001-F001.PNG</pub-id><pub-id pub-id-type="pmid">37546706</pub-id><pub-id pub-id-type="pmcid">PMC10400053</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Liu S, Wang Y. Diagnosis and management of adult central nervous system leukemia. Blood Sci. 2023;5(3):141&#8211;9. 10.1097/BS9.0000000000000162/ASSET/159B4FC1-205A-40B6-A9DA-E331B9FBCF3E/ASSETS/GRAPHIC/2543-6368-05-03-001-F001.PNG.<pub-id pub-id-type="pmid">37546706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/BS9.0000000000000162</pub-id><pub-id pub-id-type="pmcid">PMC10400053</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lomeli</surname><given-names>N</given-names></name><name name-style="western"><surname>Pearre</surname><given-names>DC</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>M</given-names></name><name name-style="western"><surname>Di</surname><given-names>K</given-names></name><name name-style="western"><surname>Ricks-Oddie</surname><given-names>JL</given-names></name><name name-style="western"><surname>Bota</surname><given-names>DA</given-names></name></person-group><article-title>Cisplatin induces BDNF downregulation in middle-aged female rat model while BDNF enhancement attenuates cisplatin neurotoxicity</article-title><source>Exp Neurol</source><year>2024</year><volume>375</volume><fpage>114717</fpage><pub-id pub-id-type="doi">10.1016/J.EXPNEUROL.2024.114717</pub-id><pub-id pub-id-type="pmid">38336286</pub-id><pub-id pub-id-type="pmcid">PMC11087041</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Lomeli N, Pearre DC, Cruz M, Di K, Ricks-Oddie JL, Bota DA. Cisplatin induces BDNF downregulation in middle-aged female rat model while BDNF enhancement attenuates cisplatin neurotoxicity. Exp Neurol. 2024;375:114717. 10.1016/J.EXPNEUROL.2024.114717.<pub-id pub-id-type="pmid">38336286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.expneurol.2024.114717</pub-id><pub-id pub-id-type="pmcid">PMC11087041</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Neural influences on tumor progression within the central nervous system</article-title><source>CNS Neurosci Ther</source><year>2024</year><volume>30</volume><issue>10</issue><fpage>e70097</fpage><pub-id pub-id-type="doi">10.1111/CNS.70097</pub-id><pub-id pub-id-type="pmid">39469896</pub-id><pub-id pub-id-type="pmcid">PMC11519750</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Lv W, Wang Y. Neural influences on tumor progression within the central nervous system. CNS Neurosci Ther. 2024;30(10):e70097. 10.1111/CNS.70097.<pub-id pub-id-type="pmid">39469896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cns.70097</pub-id><pub-id pub-id-type="pmcid">PMC11519750</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mancusi</surname><given-names>R</given-names></name><name name-style="western"><surname>Monje</surname><given-names>M</given-names></name></person-group><article-title>The neuroscience of cancer</article-title><source>Nature</source><year>2023</year><volume>618</volume><issue>7965</issue><fpage>467</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1038/S41586-023-05968-Y</pub-id><pub-id pub-id-type="pmid">37316719</pub-id><pub-id pub-id-type="pmcid">PMC11146751</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Mancusi R, Monje M. The neuroscience of cancer. Nature. 2023a;618(7965):467&#8211;79. 10.1038/S41586-023-05968-Y.<pub-id pub-id-type="pmid">37316719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-05968-y</pub-id><pub-id pub-id-type="pmcid">PMC11146751</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mancusi</surname><given-names>R</given-names></name><name name-style="western"><surname>Monje</surname><given-names>M</given-names></name></person-group><article-title>The neuroscience of cancer</article-title><source>Nature</source><year>2023</year><volume>618</volume><issue>7965</issue><fpage>467</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1038/S41586-023-05968-Y</pub-id><pub-id pub-id-type="pmid">37316719</pub-id><pub-id pub-id-type="pmcid">PMC11146751</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Mancusi R, Monje M. The neuroscience of cancer. Nature. 2023b;618(7965):467&#8211;79. 10.1038/S41586-023-05968-Y.<pub-id pub-id-type="pmid">37316719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-05968-y</pub-id><pub-id pub-id-type="pmcid">PMC11146751</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogunbona</surname><given-names>OB</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>AL</given-names></name><name name-style="western"><surname>Osunkoya</surname><given-names>AO</given-names></name></person-group><article-title>Metastatic prostatic adenocarcinoma to the brain and spinal cord: a contemporary clinicopathologic analysis of 30 cases</article-title><source>Int J Clin Exp Pathol</source><year>2021</year><volume>14</volume><issue>1</issue><fpage>45</fpage><pub-id pub-id-type="pmid">33532022</pub-id><pub-id pub-id-type="pmcid">PMC7847485</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Ogunbona OB, Goodman AL, Osunkoya AO. Metastatic prostatic adenocarcinoma to the brain and spinal cord: a contemporary clinicopathologic analysis of 30 cases. Int J Clin Exp Pathol. 2021;14(1):45. <ext-link ext-link-type="uri" xlink:href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7847485/">https://pmc.ncbi.nlm.nih.gov/articles/PMC7847485/</ext-link>.<pub-id pub-id-type="pmid">33532022</pub-id><pub-id pub-id-type="pmcid">PMC7847485</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oktavianda</surname><given-names>YD</given-names></name><name name-style="western"><surname>Permata</surname><given-names>TBM</given-names></name></person-group><article-title>Role of memantine to mitigate radiation-induced cognitive dysfunction in brain metastasis patient receiving whole brain radiotherapy: a systematic review</article-title><source>Radiation Oncol J</source><year>2024</year><volume>42</volume><issue>4</issue><fpage>281</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.3857/ROJ.2024.00269</pub-id><pub-id pub-id-type="pmcid">PMC11701468</pub-id><pub-id pub-id-type="pmid">39748529</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Oktavianda YD, Permata TBM. Role of memantine to mitigate radiation-induced cognitive dysfunction in brain metastasis patient receiving whole brain radiotherapy: a systematic review. Radiation Oncol J. 2024;42(4):281&#8211;94. 10.3857/ROJ.2024.00269.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3857/roj.2024.00269</pub-id><pub-id pub-id-type="pmcid">PMC11701468</pub-id><pub-id pub-id-type="pmid">39748529</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliva</surname><given-names>G</given-names></name><name name-style="western"><surname>Giustiniani</surname><given-names>A</given-names></name><name name-style="western"><surname>Danesin</surname><given-names>L</given-names></name><name name-style="western"><surname>Burgio</surname><given-names>F</given-names></name><name name-style="western"><surname>Arcara</surname><given-names>G</given-names></name><name name-style="western"><surname>Conte</surname><given-names>P</given-names></name></person-group><article-title>Cognitive impairment following breast cancer treatments: an umbrella review</article-title><source>Oncologist</source><year>2024</year><volume>29</volume><issue>7</issue><fpage>e848</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1093/ONCOLO/OYAE090</pub-id><pub-id pub-id-type="pmid">38723166</pub-id><pub-id pub-id-type="pmcid">PMC11224991</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Oliva G, Giustiniani A, Danesin L, Burgio F, Arcara G, Conte P. Cognitive impairment following breast cancer treatments: an umbrella review. Oncologist. 2024;29(7):e848&#8211;63. 10.1093/ONCOLO/OYAE090.<pub-id pub-id-type="pmid">38723166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/oncolo/oyae090</pub-id><pub-id pub-id-type="pmcid">PMC11224991</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ostrom</surname><given-names>QT</given-names></name><name name-style="western"><surname>Price</surname><given-names>M</given-names></name><name name-style="western"><surname>Neff</surname><given-names>C</given-names></name><name name-style="western"><surname>Cioffi</surname><given-names>G</given-names></name><name name-style="western"><surname>Waite</surname><given-names>KA</given-names></name><name name-style="western"><surname>Kruchko</surname><given-names>C</given-names></name><name name-style="western"><surname>Barnholtz-Sloan</surname><given-names>JS</given-names></name></person-group><article-title>CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2015&#8211;2019</article-title><source>Neurooncology</source><year>2022</year><volume>24</volume><issue>5 S</issue><fpage>V1</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1093/NEUONC/NOAC202</pub-id><pub-id pub-id-type="pmcid">PMC9533228</pub-id><pub-id pub-id-type="pmid">36196752</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2015&#8211;2019. Neurooncology. 2022;24(5 S):V1&#8211;95. 10.1093/NEUONC/NOAC202.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/neuonc/noac202</pub-id><pub-id pub-id-type="pmcid">PMC9533228</pub-id><pub-id pub-id-type="pmid">36196752</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pamboris</surname><given-names>GM</given-names></name><name name-style="western"><surname>Plakias</surname><given-names>S</given-names></name><name name-style="western"><surname>Tsiakiri</surname><given-names>A</given-names></name><name name-style="western"><surname>Karakitsiou</surname><given-names>G</given-names></name><name name-style="western"><surname>Bebeletsi</surname><given-names>P</given-names></name><name name-style="western"><surname>Vadikolias</surname><given-names>K</given-names></name><name name-style="western"><surname>Aggelousis</surname><given-names>N</given-names></name><name name-style="western"><surname>Tsiptsios</surname><given-names>D</given-names></name><name name-style="western"><surname>Christidi</surname><given-names>F</given-names></name></person-group><article-title>Physical therapy in neurorehabilitation with an emphasis on sports: A bibliometric analysis and narrative review</article-title><source>Sports</source><year>2024</year><volume>12</volume><issue>10</issue><fpage>276</fpage><pub-id pub-id-type="doi">10.3390/SPORTS12100276</pub-id><pub-id pub-id-type="pmid">39453242</pub-id><pub-id pub-id-type="pmcid">PMC11511441</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Pamboris GM, Plakias S, Tsiakiri A, Karakitsiou G, Bebeletsi P, Vadikolias K, Aggelousis N, Tsiptsios D, Christidi F. Physical therapy in neurorehabilitation with an emphasis on sports: A bibliometric analysis and narrative review. Sports. 2024;12(10):276. 10.3390/SPORTS12100276.<pub-id pub-id-type="pmid">39453242</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/sports12100276</pub-id><pub-id pub-id-type="pmcid">PMC11511441</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52</label><mixed-citation publication-type="other">Pasquini L, Peck KK, Jenabi M, Holodny A. Functional MRI in Neuro-Oncology: state of the Art and future directions. Radiology. 2023;308(3). 10.1148/RADIOL.222028.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.222028</pub-id><pub-id pub-id-type="pmcid">PMC10546288</pub-id><pub-id pub-id-type="pmid">37668519</pub-id></mixed-citation></ref><ref id="CR53"><label>53</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petr</surname><given-names>J</given-names></name><name name-style="western"><surname>Hogeboom</surname><given-names>L</given-names></name><name name-style="western"><surname>Nikulin</surname><given-names>P</given-names></name><name name-style="western"><surname>Wiegers</surname><given-names>E</given-names></name><name name-style="western"><surname>Schroyen</surname><given-names>G</given-names></name><name name-style="western"><surname>Kallehauge</surname><given-names>J</given-names></name><name name-style="western"><surname>Chmel&#237;k</surname><given-names>M</given-names></name><name name-style="western"><surname>Clement</surname><given-names>P</given-names></name><name name-style="western"><surname>Nechifor</surname><given-names>RE</given-names></name><name name-style="western"><surname>Fodor</surname><given-names>LA</given-names></name><name name-style="western"><surname>De Witt Hamer</surname><given-names>PC</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F</given-names></name><name name-style="western"><surname>Pernet</surname><given-names>C</given-names></name><name name-style="western"><surname>Lequin</surname><given-names>M</given-names></name><name name-style="western"><surname>Deprez</surname><given-names>S</given-names></name><name name-style="western"><surname>Jan&#269;&#225;lek</surname><given-names>R</given-names></name><name name-style="western"><surname>Mutsaerts</surname><given-names>HJ</given-names></name><name name-style="western"><surname>M. M., Pizzini</surname><given-names>FB</given-names></name><name name-style="western"><surname>Emblem</surname><given-names>KE</given-names></name><name name-style="western"><surname>Keil</surname><given-names>VC</given-names></name></person-group><article-title>A systematic review on the use of quantitative imaging to detect cancer therapy adverse effects in normal-appearing brain tissue</article-title><source>Magn Reson Mater Phys Biol Med</source><year>2022</year><volume>35</volume><issue>1</issue><fpage>163</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1007/S10334-021-00985-2</pub-id><pub-id pub-id-type="pmcid">PMC8901489</pub-id><pub-id pub-id-type="pmid">34919195</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Petr J, Hogeboom L, Nikulin P, Wiegers E, Schroyen G, Kallehauge J, Chmel&#237;k M, Clement P, Nechifor RE, Fodor LA, De Witt Hamer PC, Barkhof F, Pernet C, Lequin M, Deprez S, Jan&#269;&#225;lek R, Mutsaerts HJ, M. M., Pizzini FB, Emblem KE, Keil VC. A systematic review on the use of quantitative imaging to detect cancer therapy adverse effects in normal-appearing brain tissue. Magn Reson Mater Phys Biol Med. 2022;35(1):163&#8211;86. 10.1007/S10334-021-00985-2.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10334-021-00985-2</pub-id><pub-id pub-id-type="pmcid">PMC8901489</pub-id><pub-id pub-id-type="pmid">34919195</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54</label><mixed-citation publication-type="other">Pilarska A, Pieczy&#324;ska A, Hojan K. Neuropsychological monitoring of cognitive function and ICF&#8211;based mental components in patients with malignant brain tumours. Front Psychol. 2023;14. 10.3389/fpsyg.2023.1033185.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyg.2023.1033185</pub-id><pub-id pub-id-type="pmcid">PMC10102367</pub-id><pub-id pub-id-type="pmid">37063555</pub-id></mixed-citation></ref><ref id="CR55"><label>55</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahman</surname><given-names>N</given-names></name><name name-style="western"><surname>Sukumar</surname><given-names>J</given-names></name><name name-style="western"><surname>Lustberg</surname><given-names>MB</given-names></name></person-group><article-title>Chronic chemotherapy-induced peripheral neuropathy: living with neuropathy during and after cancer treatments</article-title><source>Annals Palliat Med</source><year>2025</year><volume>14</volume><issue>2</issue><fpage>19616</fpage><lpage>19216</lpage><pub-id pub-id-type="doi">10.21037/APM-24-154</pub-id><pub-id pub-id-type="pmid">40211744</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Rahman N, Sukumar J, Lustberg MB. Chronic chemotherapy-induced peripheral neuropathy: living with neuropathy during and after cancer treatments. Annals Palliat Med. 2025;14(2):19616&#8211;19216. 10.21037/APM-24-154.<pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/apm-24-154</pub-id><pub-id pub-id-type="pmid">40211744</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56</label><mixed-citation publication-type="other">Ranzenberger LR, Das JM, Snyder T. (2023). Diffusion TensorImaging. <italic toggle="yes">Surgery of Spinal Cord Tumors Based on Anatomy: An Approach Based on Anatomic Compartmentalization</italic>, 147&#8211;151. 10.1007/978-981-15-7771-0_16</mixed-citation></ref><ref id="CR57"><label>57</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ristori</surname><given-names>S</given-names></name><name name-style="western"><surname>Bertoni</surname><given-names>G</given-names></name><name name-style="western"><surname>Bientinesi</surname><given-names>E</given-names></name><name name-style="western"><surname>Monti</surname><given-names>D</given-names></name></person-group><article-title>The role of nutraceuticals and functional foods in mitigating cellular senescence and its related aspects: A key strategy for delaying or preventing aging and neurodegenerative disorders</article-title><source>Nutrients 2025</source><year>2025</year><volume>17</volume><issue>11</issue><fpage>1837</fpage><pub-id pub-id-type="doi">10.3390/NU17111837</pub-id><pub-id pub-id-type="pmcid">PMC12157746</pub-id><pub-id pub-id-type="pmid">40507106</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Ristori S, Bertoni G, Bientinesi E, Monti D. The role of nutraceuticals and functional foods in mitigating cellular senescence and its related aspects: A key strategy for delaying or preventing aging and neurodegenerative disorders. Nutrients 2025. 2025;17(11):1837. 10.3390/NU17111837. <italic toggle="yes">17</italic>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu17111837</pub-id><pub-id pub-id-type="pmcid">PMC12157746</pub-id><pub-id pub-id-type="pmid">40507106</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Naidoo</surname><given-names>J</given-names></name><name name-style="western"><surname>Santomasso</surname><given-names>BD</given-names></name><name name-style="western"><surname>Lacchetti</surname><given-names>C</given-names></name><name name-style="western"><surname>Adkins</surname><given-names>S</given-names></name><name name-style="western"><surname>Anadkat</surname><given-names>M</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>MB</given-names></name><name name-style="western"><surname>Brassil</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Caterino</surname><given-names>JM</given-names></name><name name-style="western"><surname>Chau</surname><given-names>I</given-names></name><name name-style="western"><surname>Davies</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Ernstoff</surname><given-names>MS</given-names></name><name name-style="western"><surname>Fecher</surname><given-names>L</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>M</given-names></name><name name-style="western"><surname>Jaiyesimi</surname><given-names>I</given-names></name><name name-style="western"><surname>Mammen</surname><given-names>JS</given-names></name><name name-style="western"><surname>Naing</surname><given-names>A</given-names></name><name name-style="western"><surname>Nastoupil</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>T</given-names></name><name name-style="western"><surname>Bollin</surname><given-names>K</given-names></name></person-group><article-title>Management of immune-Related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update</article-title><source>J Clin Oncol</source><year>2021</year><volume>39</volume><issue>36</issue><fpage>4073</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1200/JCO.21.01440</pub-id><pub-id pub-id-type="pmid">34724392</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Bollin K. Management of immune-Related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073&#8211;126. 10.1200/JCO.21.01440.<pub-id pub-id-type="pmid">34724392</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.21.01440</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Souza-Couto</surname><given-names>D</given-names></name><name name-style="western"><surname>Bretas</surname><given-names>R</given-names></name><name name-style="western"><surname>Aversi-Ferreira</surname><given-names>TA</given-names></name></person-group><article-title>Neuropsychology of the parietal lobe: luria&#8217;s and contemporary conceptions</article-title><source>Front NeuroSci</source><year>2023</year><volume>17</volume><fpage>1226226</fpage><pub-id pub-id-type="doi">10.3389/FNINS.2023.1226226/XML</pub-id><pub-id pub-id-type="pmid">37928730</pub-id><pub-id pub-id-type="pmcid">PMC10623013</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Souza-Couto D, Bretas R, Aversi-Ferreira TA. Neuropsychology of the parietal lobe: luria&#8217;s and contemporary conceptions. Front NeuroSci. 2023;17:1226226. 10.3389/FNINS.2023.1226226/XML.<pub-id pub-id-type="pmid">37928730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2023.1226226</pub-id><pub-id pub-id-type="pmcid">PMC10623013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taams</surname><given-names>LS</given-names></name></person-group><article-title>Neuroimmune interactions: how the nervous and immune systems influence each other</article-title><source>Clin Exp Immunol</source><year>2019</year><volume>197</volume><issue>3</issue><fpage>276</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/cei.13355</pub-id><pub-id pub-id-type="pmid">31412421</pub-id><pub-id pub-id-type="pmcid">PMC6693962</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Taams LS. Neuroimmune interactions: how the nervous and immune systems influence each other. Clin Exp Immunol. 2019;197(3):276&#8211;7. 10.1111/cei.13355.<pub-id pub-id-type="pmid">31412421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cei.13355</pub-id><pub-id pub-id-type="pmcid">PMC6693962</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61</label><mixed-citation publication-type="other">Tirthani E, Said MS, Smith RG, Jadhav N, Shanina E. (2023). Paraneoplastic Encephalomyelitis. <italic toggle="yes">StatPearls</italic>. <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK564519/">https://www.ncbi.nlm.nih.gov/books/NBK564519/</ext-link><pub-id pub-id-type="pmid">33232100</pub-id></mixed-citation></ref><ref id="CR62"><label>62</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van den Bent</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Geurts</surname><given-names>M</given-names></name><name name-style="western"><surname>French</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Smits</surname><given-names>M</given-names></name><name name-style="western"><surname>Capper</surname><given-names>D</given-names></name><name name-style="western"><surname>Bromberg</surname><given-names>JEC</given-names></name><name name-style="western"><surname>Chang</surname><given-names>SM</given-names></name></person-group><article-title>Primary brain tumours inadults</article-title><source>Lancet</source><year>2023</year><volume>402</volume><issue>10412</issue><fpage>1564</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(23)01054-1</pub-id><pub-id pub-id-type="pmid">37738997</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">van den Bent MJ, Geurts M, French PJ, Smits M, Capper D, Bromberg JEC, Chang SM. Primary brain tumours in adults. Lancet. 2023;402(10412):1564&#8211;79. 10.1016/S0140-6736(23)01054-1.<pub-id pub-id-type="pmid">37738997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(23)01054-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Dijk</surname><given-names>B</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>JC</given-names></name><name name-style="western"><surname>van Daele</surname><given-names>PLA</given-names></name><name name-style="western"><surname>de Jonge</surname><given-names>MJA</given-names></name><name name-style="western"><surname>Joosse</surname><given-names>A</given-names></name><name name-style="western"><surname>Verheul</surname><given-names>HMW</given-names></name><name name-style="western"><surname>Epker</surname><given-names>JL</given-names></name><name name-style="western"><surname>van der Veldt</surname><given-names>AAM</given-names></name></person-group><article-title>From ICI to ICU: A systematic review of patients with solid tumors who are treated with immune checkpoint inhibitors (ICI) and admitted to the intensive care unit (ICU)</article-title><source>Cancer Treat Rev</source><year>2025</year><volume>136</volume><fpage>102936</fpage><pub-id pub-id-type="doi">10.1016/J.CTRV.2025.102936</pub-id><pub-id pub-id-type="pmid">40222269</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">van Dijk B, Janssen JC, van Daele PLA, de Jonge MJA, Joosse A, Verheul HMW, Epker JL, van der Veldt AAM. From ICI to ICU: A systematic review of patients with solid tumors who are treated with immune checkpoint inhibitors (ICI) and admitted to the intensive care unit (ICU). Cancer Treat Rev. 2025;136:102936. 10.1016/J.CTRV.2025.102936.<pub-id pub-id-type="pmid">40222269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ctrv.2025.102936</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Was</surname><given-names>H</given-names></name><name name-style="western"><surname>Borkowska</surname><given-names>A</given-names></name><name name-style="western"><surname>Bagues</surname><given-names>A</given-names></name><name name-style="western"><surname>Tu</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>JYH</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Rudd</surname><given-names>JA</given-names></name><name name-style="western"><surname>Nurgali</surname><given-names>K</given-names></name><name name-style="western"><surname>Abalo</surname><given-names>R</given-names></name></person-group><article-title>Mechanisms of Chemotherapy-Induced neurotoxicity</article-title><source>Front Pharmacol</source><year>2022</year><volume>13</volume><fpage>750507</fpage><pub-id pub-id-type="doi">10.3389/FPHAR.2022.750507</pub-id><pub-id pub-id-type="pmid">35418856</pub-id><pub-id pub-id-type="pmcid">PMC8996259</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Was H, Borkowska A, Bagues A, Tu L, Liu JYH, Lu Z, Rudd JA, Nurgali K, Abalo R. Mechanisms of Chemotherapy-Induced neurotoxicity. Front Pharmacol. 2022a;13:750507. 10.3389/FPHAR.2022.750507.<pub-id pub-id-type="pmid">35418856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2022.750507</pub-id><pub-id pub-id-type="pmcid">PMC8996259</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Was</surname><given-names>H</given-names></name><name name-style="western"><surname>Borkowska</surname><given-names>A</given-names></name><name name-style="western"><surname>Bagues</surname><given-names>A</given-names></name><name name-style="western"><surname>Tu</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>JYH</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Rudd</surname><given-names>JA</given-names></name><name name-style="western"><surname>Nurgali</surname><given-names>K</given-names></name><name name-style="western"><surname>Abalo</surname><given-names>R</given-names></name></person-group><article-title>Mechanisms of Chemotherapy-Induced neurotoxicity</article-title><source>Front Pharmacol</source><year>2022</year><volume>13</volume><fpage>750507</fpage><pub-id pub-id-type="doi">10.3389/FPHAR.2022.750507/XML/NLM</pub-id><pub-id pub-id-type="pmid">35418856</pub-id><pub-id pub-id-type="pmcid">PMC8996259</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Was H, Borkowska A, Bagues A, Tu L, Liu JYH, Lu Z, Rudd JA, Nurgali K, Abalo R. Mechanisms of Chemotherapy-Induced neurotoxicity. Front Pharmacol. 2022b;13:750507. 10.3389/FPHAR.2022.750507/XML/NLM.<pub-id pub-id-type="pmid">35418856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2022.750507</pub-id><pub-id pub-id-type="pmcid">PMC8996259</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wujanto</surname><given-names>C</given-names></name><name name-style="western"><surname>Vellayappan</surname><given-names>B</given-names></name><name name-style="western"><surname>Chang</surname><given-names>EL</given-names></name><name name-style="western"><surname>Chao</surname><given-names>ST</given-names></name><name name-style="western"><surname>Sahgal</surname><given-names>A</given-names></name><name name-style="western"><surname>Lo</surname><given-names>SS</given-names></name></person-group><article-title>Radiotherapy to the brain: what are the consequences of this age-old treatment?</article-title><source>Annals Palliat Med</source><year>2021</year><volume>10</volume><issue>1</issue><fpage>93652</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.21037/APM-20-856</pub-id><pub-id pub-id-type="pmid">32787351</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Wujanto C, Vellayappan B, Chang EL, Chao ST, Sahgal A, Lo SS. Radiotherapy to the brain: what are the consequences of this age-old treatment? Annals Palliat Med. 2021;10(1):93652&#8211;952. 10.21037/APM-20-856.<pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/apm-20-856</pub-id><pub-id pub-id-type="pmid">32787351</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67</label><mixed-citation publication-type="other">Xiang Y, Zhang M, Jiang D, Su Q, Shi J. The role of inflammation in autoimmune disease: a therapeutic target. Front Immunol. 2023;14. 10.3389/FIMMU.2023.1267091.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1267091</pub-id><pub-id pub-id-type="pmcid">PMC10584158</pub-id><pub-id pub-id-type="pmid">37859999</pub-id></mixed-citation></ref><ref id="CR68"><label>68</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>X</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Q</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies</article-title><source>J Experimental Clin Cancer Res</source><year>2021</year><volume>2021 40:1</volume><issue>1</issue><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1186/S13046-021-02148-6</pub-id><pub-id pub-id-type="pmcid">PMC8600921</pub-id><pub-id pub-id-type="pmid">34794490</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, Li Y. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Experimental Clin Cancer Res. 2021;2021 40:1(1):1&#8211;23. 10.1186/S13046-021-02148-6. <italic toggle="yes">40</italic>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-021-02148-6</pub-id><pub-id pub-id-type="pmcid">PMC8600921</pub-id><pub-id pub-id-type="pmid">34794490</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>A</given-names></name><name name-style="western"><surname>Nixon</surname><given-names>RA</given-names></name></person-group><article-title>Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies</article-title><source>Front NeuroSci</source><year>2021</year><volume>15</volume><fpage>689938</fpage><pub-id pub-id-type="doi">10.3389/FNINS.2021.689938</pub-id><pub-id pub-id-type="pmid">34646114</pub-id><pub-id pub-id-type="pmcid">PMC8503617</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Yuan A, Nixon RA. Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies. Front NeuroSci. 2021;15:689938. 10.3389/FNINS.2021.689938.<pub-id pub-id-type="pmid">34646114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2021.689938</pub-id><pub-id pub-id-type="pmcid">PMC8503617</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Y&#252;ceer</surname><given-names>H</given-names></name><name name-style="western"><surname>T&#252;z&#252;n</surname><given-names>E</given-names></name></person-group><article-title>Biomarker value of neurofilaments and glial fibrillary acidic protein in central nervous system lymphoma and tumors</article-title><source>Archives Neuropsychiatry</source><year>2022</year><volume>59</volume><issue>4</issue><fpage>253</fpage><pub-id pub-id-type="doi">10.29399/NPA.28312</pub-id><pub-id pub-id-type="pmcid">PMC9723831</pub-id><pub-id pub-id-type="pmid">36514520</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Y&#252;ceer H, T&#252;z&#252;n E. Biomarker value of neurofilaments and glial fibrillary acidic protein in central nervous system lymphoma and tumors. Archives Neuropsychiatry. 2022;59(4):253. 10.29399/NPA.28312.<pub-id pub-id-type="doi" assigning-authority="pmc">10.29399/npa.28312</pub-id><pub-id pub-id-type="pmcid">PMC9723831</pub-id><pub-id pub-id-type="pmid">36514520</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71</label><mixed-citation publication-type="other">Zeiser R, Prinz M. Immune checkpoint inhibitor induced neurocognitive deficits in patients. Brain Commun. 2023;5(3). 10.1093/BRAINCOMMS/FCAD186.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcad186</pub-id><pub-id pub-id-type="pmcid">PMC10306159</pub-id><pub-id pub-id-type="pmid">37389305</pub-id></mixed-citation></ref><ref id="CR72"><label>72</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmer</surname><given-names>AS</given-names></name></person-group><article-title>Triple-negative breast cancer central nervous system metastases from the laboratory to the clinic</article-title><source>Cancer J (Sudbury Mass)</source><year>2021</year><volume>27</volume><issue>1</issue><fpage>76</fpage><pub-id pub-id-type="doi">10.1097/PPO.0000000000000503</pub-id><pub-id pub-id-type="pmcid">PMC7839270</pub-id><pub-id pub-id-type="pmid">33475296</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Zimmer AS. Triple-negative breast cancer central nervous system metastases from the laboratory to the clinic. Cancer J (Sudbury Mass). 2021;27(1):76. 10.1097/PPO.0000000000000503.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PPO.0000000000000503</pub-id><pub-id pub-id-type="pmcid">PMC7839270</pub-id><pub-id pub-id-type="pmid">33475296</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>